US20130338349A1 - Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives - Google Patents
Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives Download PDFInfo
- Publication number
- US20130338349A1 US20130338349A1 US13/917,173 US201313917173A US2013338349A1 US 20130338349 A1 US20130338349 A1 US 20130338349A1 US 201313917173 A US201313917173 A US 201313917173A US 2013338349 A1 US2013338349 A1 US 2013338349A1
- Authority
- US
- United States
- Prior art keywords
- optionally substituted
- lower alkyl
- compound
- alkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](N3C=CC(NC(=O)C4=CC=CC=C4)=NC3=O)C(=O)[C@H]2O[Si](C(C)C)(C(C)C)O1.CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](N3C=CC(NC(=O)C4=CC=CC=C4)=NC3=O)C(C)(O)[C@H]2O[Si](C(C)C)(C(C)C)O1.CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](N3C=CC(NC(=O)C4=CC=CC=C4)=NC3=O)C(C)(O)[C@H]2O[Si](C(C)C)(C(C)C)O1.CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](N3C=CC(NC(=O)C4=CC=CC=C4)=NC3=O)C(O)[C@H]2O[Si](C(C)C)(C(C)C)O1.CC1(F)[C@@H](*O)[C@@H](C*O)O[C@H]1N1C=CC(NC(=O)C2=CC=CC=C2)=NC1=O.CC1(O)[C@@H](*O)[C@@H](C*O)O[C@H]1N1C=CC(NC(=O)C2=CC=CC=C2)=NC1=O.CC1(O)[C@@H](*O)[C@@H](C*O)O[C@H]1N1C=CC(NC(=O)C2=CC=CC=C2)=NC1=O.NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@H](O)C2O)C=C1 Chemical compound CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](N3C=CC(NC(=O)C4=CC=CC=C4)=NC3=O)C(=O)[C@H]2O[Si](C(C)C)(C(C)C)O1.CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](N3C=CC(NC(=O)C4=CC=CC=C4)=NC3=O)C(C)(O)[C@H]2O[Si](C(C)C)(C(C)C)O1.CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](N3C=CC(NC(=O)C4=CC=CC=C4)=NC3=O)C(C)(O)[C@H]2O[Si](C(C)C)(C(C)C)O1.CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](N3C=CC(NC(=O)C4=CC=CC=C4)=NC3=O)C(O)[C@H]2O[Si](C(C)C)(C(C)C)O1.CC1(F)[C@@H](*O)[C@@H](C*O)O[C@H]1N1C=CC(NC(=O)C2=CC=CC=C2)=NC1=O.CC1(O)[C@@H](*O)[C@@H](C*O)O[C@H]1N1C=CC(NC(=O)C2=CC=CC=C2)=NC1=O.CC1(O)[C@@H](*O)[C@@H](C*O)O[C@H]1N1C=CC(NC(=O)C2=CC=CC=C2)=NC1=O.NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@H](O)C2O)C=C1 0.000 description 21
- OTMSDBZUPAUEDD-UHFFFAOYSA-N CC Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- PVMQHURIEPRDEC-MSESJSDLSA-N CC1(F)[C@@H](O)[C@@H](CO)O[C@H]1N1C=CC(N)=NC1=O.CC[C@H]1O[C@@H](N2C=CC(NC(=O)C3=CC=CC=C3)=NC2=O)C(C)(F)[C@H]1C.CC[C@H]1O[C@@H](OC(C)=O)C(C)(F)[C@H]1C.CC[C@H]1O[C@@H](OC)C(=O)[C@H]1C.CC[C@H]1O[C@@H](OC)C(C)(F)[C@H]1C.CC[C@H]1O[C@@H](OC)C(C)(O)[C@H]1C.CC[C@H]1O[C@@H](OC)C(O)[C@H]1C.CC[C@H]1O[C@H](OC)C(OC)C1=O.CC[C@H]1O[C@H](OC)C(OC)[C@@H]1O.CC[C@H]1O[C@H](OC)C(OC)[C@H]1C.CC[C@H]1O[C@H](OC)C(OC)[C@H]1O.COC1[C@@H](OC)O[C@H](CO)[C@H]1O.COC[C@H]1O[C@H](OC)C(OC)[C@@H]1OC.OC1COC(O)C(O)C1O Chemical compound CC1(F)[C@@H](O)[C@@H](CO)O[C@H]1N1C=CC(N)=NC1=O.CC[C@H]1O[C@@H](N2C=CC(NC(=O)C3=CC=CC=C3)=NC2=O)C(C)(F)[C@H]1C.CC[C@H]1O[C@@H](OC(C)=O)C(C)(F)[C@H]1C.CC[C@H]1O[C@@H](OC)C(=O)[C@H]1C.CC[C@H]1O[C@@H](OC)C(C)(F)[C@H]1C.CC[C@H]1O[C@@H](OC)C(C)(O)[C@H]1C.CC[C@H]1O[C@@H](OC)C(O)[C@H]1C.CC[C@H]1O[C@H](OC)C(OC)C1=O.CC[C@H]1O[C@H](OC)C(OC)[C@@H]1O.CC[C@H]1O[C@H](OC)C(OC)[C@H]1C.CC[C@H]1O[C@H](OC)C(OC)[C@H]1O.COC1[C@@H](OC)O[C@H](CO)[C@H]1O.COC[C@H]1O[C@H](OC)C(OC)[C@@H]1OC.OC1COC(O)C(O)C1O PVMQHURIEPRDEC-MSESJSDLSA-N 0.000 description 1
- VDXPUDCHQYARON-UHFFFAOYSA-M CC1O[Mn]([O-])(O)OC1C.CC1O[Os](=O)(=O)OC1C Chemical compound CC1O[Mn]([O-])(O)OC1C.CC1O[Os](=O)(=O)OC1C VDXPUDCHQYARON-UHFFFAOYSA-M 0.000 description 1
- ZNUJOZJLTZQGBT-UHFFFAOYSA-N CCC1OC(C)C(C)(F)C1C Chemical compound CCC1OC(C)C(C)(F)C1C ZNUJOZJLTZQGBT-UHFFFAOYSA-N 0.000 description 1
- NLKDJXRFZCLFBV-JHAUEQIYSA-N CCOC(=O)C(C)=P(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.CC[C@H]1OC(=O)[C@](C)(F)[C@@H]1C.C[C@@H]1[C@@H](CO)OC(=O)[C@]1(C)F.[H]/C(=C(/C)C(=O)OCC)[C@H]1COC(C)(C)O1.[H]C(=O)[C@H]1COC(C)(C)O1.[H][C@@](O)([C@H]1COC(C)(C)O1)[C@](C)(O)C(=O)OCC.[H][C@@](OC(=O)C1=CC=CC=C1)([C@H](O)CO)[C@@](C)(F)C(=O)OCC.[H][C@@](OC(=O)C1=CC=CC=C1)([C@H]1COC(C)(C)O1)[C@@](C)(F)C(=O)OCC.[H][C@@](OC(=O)C1=CC=CC=C1)([C@H]1COC(C)(C)O1)[C@](C)(O)C(=O)OCC Chemical compound CCOC(=O)C(C)=P(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.CC[C@H]1OC(=O)[C@](C)(F)[C@@H]1C.C[C@@H]1[C@@H](CO)OC(=O)[C@]1(C)F.[H]/C(=C(/C)C(=O)OCC)[C@H]1COC(C)(C)O1.[H]C(=O)[C@H]1COC(C)(C)O1.[H][C@@](O)([C@H]1COC(C)(C)O1)[C@](C)(O)C(=O)OCC.[H][C@@](OC(=O)C1=CC=CC=C1)([C@H](O)CO)[C@@](C)(F)C(=O)OCC.[H][C@@](OC(=O)C1=CC=CC=C1)([C@H]1COC(C)(C)O1)[C@@](C)(F)C(=O)OCC.[H][C@@](OC(=O)C1=CC=CC=C1)([C@H]1COC(C)(C)O1)[C@](C)(O)C(=O)OCC NLKDJXRFZCLFBV-JHAUEQIYSA-N 0.000 description 1
- BHCHXRCKXIVVCN-XLDPMVHQSA-N CCOC(=O)[C@@](C)(O)[C@H](O)[C@H]1COC(C)(C)O1 Chemical compound CCOC(=O)[C@@](C)(O)[C@H](O)[C@H]1COC(C)(C)O1 BHCHXRCKXIVVCN-XLDPMVHQSA-N 0.000 description 1
- UYMLTUZYEYHYHO-XLDPMVHQSA-N CCOC(=O)[C@@]1(C)OS(=O)(=O)O[C@@H]1[C@H]1COC(C)(C)O1 Chemical compound CCOC(=O)[C@@]1(C)OS(=O)(=O)O[C@@H]1[C@H]1COC(C)(C)O1 UYMLTUZYEYHYHO-XLDPMVHQSA-N 0.000 description 1
- MZDMOWULSNSZBM-LZJGTQSGSA-N CC[C@H]1OC(=O)[C@@](C)(O)[C@@H]1C.CC[C@H]1OC(=O)[C@](C)(F)[C@@H]1C.CC[C@H]1OC(=O)[C@](C)(O)[C@@H]1C.C[C@@]1(O)C(=O)O[C@H](CO)[C@H]1O.[H][C@@](O)([C@H](O)CO)[C@](C)(O)C(=O)OCC.[H][C@@](O)([C@H]1COC(C)(C)O1)[C@](C)(O)C(=O)OCC Chemical compound CC[C@H]1OC(=O)[C@@](C)(O)[C@@H]1C.CC[C@H]1OC(=O)[C@](C)(F)[C@@H]1C.CC[C@H]1OC(=O)[C@](C)(O)[C@@H]1C.C[C@@]1(O)C(=O)O[C@H](CO)[C@H]1O.[H][C@@](O)([C@H](O)CO)[C@](C)(O)C(=O)OCC.[H][C@@](O)([C@H]1COC(C)(C)O1)[C@](C)(O)C(=O)OCC MZDMOWULSNSZBM-LZJGTQSGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Definitions
- the present invention provides (i) processes for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2′-deoxy-2′-fluoro-2′-C-methyl- ⁇ -D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
- HCV infection has reached epidemic levels worldwide, and has tragic effects on the infected patients.
- drugs available for treatment of chronic hepatitis C are various forms of alpha interferon (IFN-a), either alone or in combination with ribavirin.
- IFN-a alpha interferon
- the therapeutic value of these treatments has been compromised largely due to adverse effects, which highlights the need for development of additional options for treatment.
- HCV is a small, enveloped virus in the Flaviviridae family, with a positive single-stranded RNA genome of ⁇ 9.6 kb within the nucleocapsid.
- the genome contains a single open reading frame (ORF) encoding a polyprotein of just over 3,000 amino acids, which is cleaved to generate the mature structural and nonstructural viral proteins.
- ORF is flanked by 5′ and 3′ non-translated regions (NTRs) of a few hundred nucleotides in length, which are important for RNA translation and replication.
- the translated polyprotein contains the structural core (C) and envelope proteins (E1, E2, p7) at the N-terminus, followed by the nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B).
- the mature structural proteins are generated via cleavage by the host signal peptidase.
- the junction between NS2 and NS3 is autocatalytically cleaved by the NS2/NS3 protease, while the remaining four junctions are cleaved by the N-terminal serine protease domain of NS3 complexed with NS4A.
- the NS3 protein also contains the NTP-dependent helicase activity which unwinds duplex RNA during replication.
- the NS5B protein possesses RNA-dependent RNA polymerase (RDRP) activity, which is essential for viral replication. Unlike HBV or HIV, no DNA is involved in the replication of HCV.
- RDRP RNA-dependent RNA polymerase
- the present invention as disclosed herein relates to various intermediates and synthetic methods for the preparation of compounds of general formulas [I] and [II],
- the present invention provides an efficient preparation of nucleosides and intermediates containing the 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranosyl moiety.
- both R a can be carbon, both R a can be nitrogen, or one R a can be carbon and the other R a nitrogen.
- enantiomerically pure or “enantiomerically enriched” refers to a nucleoside composition that comprises at least approximately 95%, and preferably approximately 97%, 98%, 99% or 100% of a single enantiomer of that nucleoside.
- the term “substantially free of” or “substantially in the absence of” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside.
- the compounds are substantially free of enantiomers
- alkyl refers to a saturated straight or branched hydrocarbon chain of typically C 1 to C 10 , and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl, and the like.
- the term includes both substituted and unsubstituted alkyl groups.
- Alkyl groups can be optionally substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate.
- One or more of the hydrogen atoms attached to carbon atom on alkyl may be replaced by one or more halogen atoms, e.g. fluorine or chlorine or both, such as trifluoromethyl, difluoromethyl, fluorochloromethyl, and the like.
- the hydrocarbon chain may also be interrupted by a heteroatom, such as N, O or S.
- lower alkyl refers to a C 1 to C 4 saturated straight or branched alkyl group, including both substituted and unsubstituted forms as defined above. Unless otherwise specifically stated in this application, when alkyl is a suitable moiety, lower alkyl is preferred. Similarly, when alkyl or lower alkyl is a suitable moiety, unsubstituted alkyl or lower alkyl is preferred.
- cycloalkyl refers to a saturated hydrocarbon ring having 3-8 carbon atoms, preferably, 3-6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- the cycloalkyl group may also be substituted on the ring by an alkyl group, such as cyclopropylmethyl and the like.
- alkylamino or arylamino refer to an amino group that has one or two alkyl or aryl substituents, respectively.
- protected refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes.
- oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
- Non-limiting examples include: C(O)-alkyl, C(O)Ph, C(O)aryl, CH 3 , CH 2 -alkyl, CH 2 -alkenyl, CH 2 Ph, CH 2 -aryl, CH 2 O-alkyl, CH 2 O-aryl, SO 2 -alkyl, SO 2 -aryl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, and 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).
- aryl refers to phenyl, biphenyl, or naphthyl, and preferably phenyl.
- the term includes both substituted and unsubstituted moieties.
- the aryl group can be substituted with one or more substituents, including, but not limited to hydroxyl, halo, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis,” 3rd ed., John Wiley & Sons, 1999.
- alkaryl or “alkylaryl” refer to an alkyl group with an aryl substituent.
- aralkyl or arylalkyl refer to an aryl group with an alkyl substituent, as for example, benzyl.
- halo includes chloro, bromo, iodo and fluoro.
- acyl ester or “O-linked ester” refers to a carboxylic acid ester of the formula C(O)R′ in which the non-carbonyl moiety of the ester group, R′, is a straight or branched alkyl, or cycloalkyl or lower alkyl, alkoxyalkyl including methoxymethyl, aralkyl including benzyl, aryloxyalkyl such as phenoxymethyl, aryl including phenyl optionally substituted with halogen (F, Cl, Br, I), C 1 to C 4 alkyl or C 1 to C 4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butyl silyl) or diphenyl
- acyl refers to a group of the formula R′′C(O)—, wherein R′′ is a straight or branched alkyl, or cycloalkyl, amino acid, aryl including phenyl, alkylaryl, aralkyl including benzyl, alkoxyalkyl including methoxymethyl, aryloxyalkyl such as phenoxymethyl; or substituted alkyl (including lower alkyl), aryl including phenyl optionally substituted with chloro, bromo, fluoro, iodo, C 1 to C 4 alkyl or C 1 to C 4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxy-trityl, substituted benzyl, alkaryl, aralkyl including benzyl, alkoxyalkyl including me
- Aryl groups in the esters optimally comprise a phenyl group.
- acyl groups include acetyl, trifluoroacetyl, methylacetyl, cyclopropylacetyl, cyclopropyl carboxy, propionyl, butyryl, isobutyryl, hexanoyl, heptanoyl, octanoyl, neo-heptanoyl, phenylacetyl, 2-acetoxy-2-phenylacetyl, diphenylacetyl, ⁇ -methoxy- ⁇ -trifluoromethyl-phenylacetyl, bromoacetyl, 2-nitro-benzeneacetyl, 4-chloro-benzeneacetyl, 2-chloro-2,2-diphenylacetyl, 2-chloro-2-phenylacetyl, trimethylacetyl, chlorodifluoroacetyl, perfluoroacet
- acyl when the term acyl is used, it is meant to be a specific and independent disclosure of acetyl, trifluoroacetyl, methylacetyl, cyclopropylacetyl, propionyl, butyryl, isobutyryl, hexanoyl, heptanoyl, octanoyl, neo-heptanoyl, phenylacetyl, diphenylacetyl, ct-trifluoromethyl-phenylacetyl, bromoacetyl, 4-chloro-benzeneacetyl, 2-chloro-2,2-diphenylacetyl, 2-chloro-2-phenylacetyl, trimethylacetyl, chlorodifluoroacetyl, perfluoroacetyl, fluoroacetyl, bromodifluoroacetyl, 2-thiopheneacetyl, tert-butylace
- lower acyl refers to an acyl group in which R′′, above defined, is lower alkyl.
- nucleic base and “modified nucleic base” refer to “purine” or “pyrimidine” bases as defined below.
- purine or “pyrimidine” base includes, but is not limited to, adenine, N 6 -alkylpurines, N 6 -acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N 6 -benzylpurine, N 6 -halopurine, N 6 -vinylpurine, N 6 -acetylenic purine, N 6 -acyl purine, N 6 -hydroxyalkyl purine, N 6 -allylaminopurine, N 6 -thioallyl purine, N 6 -alkylpurines, N 2 -alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrimidine, uracil, 5-halouracil, including 5-fluorouracil, C 5
- Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.
- amino acid includes naturally occurring and synthetic ⁇ , ⁇ ⁇ or ⁇ amino acids, and includes but is not limited to, amino acids found in proteins, i.e. glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine.
- the amino acid is in the L-configuration.
- the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, ⁇ -alanyl, ⁇ -valinyl, ⁇ -leucinyl, ⁇ -isoleucinyl, ⁇ -prolinyl, ⁇ -phenylalaninyl, ⁇ -tryptophanyl, ⁇ -methioninyl, ⁇ -glycinyl, ⁇ -serinyl, ⁇ -threoninyl, ⁇ -cysteinyl
- amino acid When the term amino acid is used, it is considered to be a specific and independent disclosure of each of the esters of ⁇ , ⁇ or ⁇ glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine in the D and L-configurations.
- pharmaceutically acceptable salt or prodrug is used throughput the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a compound which, upon administration to a patient, provides the active compound.
- Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. Pharmaceutically acceptable salts may also be acid addition salts when formed with a nitrogen atom.
- Such salts are derived from pharmaceutically acceptable inorganic or organic acids, such as hydrochloric, sulfuric, phosphoric, acetic, citric, tartaric, and the like.
- Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
- Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
- This invention relates to the process for the preparation of the 2′-F-nucleosides and other 2′-substituted nucleosides of the general formula IB and IB-L- by using the nucleophilic opening of the cyclic sulfite, IIIa (X ⁇ SO), sulfate, IIIb (X ⁇ SO 2 ), of the formula, III in highly stereospecific and regioselective manner, via the lactones of the formula, IV.
- the present invention as disclosed herein relates to processes for the synthesis of a compound, 2-alkyl-4,5-di-O-protected-2,3-dihydroxy-pentanoic-acid ester of the following general formula 42B, which is the important intermediate in the synthesis of anti-HCV nucleosides of general formulas [I] and [II] (below).
- R′, R′′ isopropylidene, benzylidene or cyclohexylidene or a like, or a part of cyclic group including ethylene (—CH 2 CH 2 —), or trimethylene (—CH 2 CH 2 CH 2 —) forming cyclopentyl or cyclohexanyl group, respectively;
- R′ and R′′ can be independently lower alkyl of C 1 -C 6 , or aryl of C 6 -C 20 ), benzyl and other optionally substituted benzyl, trialkylsilyl, t-butyl-dialkylsyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, MEM and other optionally ether protecting groups; or H, acetyl, benzoyl and other optionally substituted acyl (R′ and R′′ are —C(O)—R, wherein R can be lower alkyl of C 1 -C 6 , or ary
- R 1 , R 2 are independently hydrogen, aryl (C 6 -C 20 ) and a lower alkyl (C 1 -C 6 ) including methyl, hydroxymethyl, methoxymethyl, halomethyl including fluoromethyl, ethyl, propyl, optionally substituted ethenyl including vinyl, halovinyl (F—CH ⁇ C), optionally substituted ethynyl including haloethynyl (F—C ⁇ C), optionally substituted allyl including haloallyl (FHC ⁇ CH—CH 2 —); and
- R 3 is independently hydrogen, aryl including phenyl, aryl alkyl including, but not limited to benzyl, lower alkyl (C 1-6 ) including methyl, ethyl, or propyl.
- the invention as disclosed herein also relates to processes for making compounds of the following general formula 49B, which are prepared from 2-alkyl-4,5-di-O-protected-2,3-dihydroxy-pentanoic-acid ester derivatives of general formula [42B].
- R 3 and R 5 can be independently H, CH 3 , Ac, Bz, pivaloyl, or 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, para-phenylbenzoyl, and other optionally substituted acyl (R 3 and R 5 are —C(O)—R, R can be independently lower alkyl of C 1 -C 6 , or aryl of C 6 -C 20 ), benzyl, 4-methoxybenzyl and other optionally substituted benzyl (R 3 and R 5 can be independently aryl of C 6 -C 20 ), trityl, trialkylsilyl, t-butyl-dialkylsyl, t-butyldiphenylsilyl, TIPDS, THP, MOM,
- (2S,3R,4R)-4,5-O-alkylidene-2-dimethyl-2,3,4,5-tetrahydroxy-2-methyl-1-pentanoic acid ethyl ester (42B) can be prepared by asymmetric dihydroxylation (AD) or stereoselective dihydroxylation of the Wittig product 41 with or without chiral catalysts.
- Wittig product 41 in turn, can be prepared readily from the protected (R) glyceraldehyde (Schemes 7, 8), where R 1 is independently a lower alkyl (C 1 -C 6 ) including, but not limited to methyl, ethyl, optionally substituted phenyl, optionally substituted benzyl.
- R 1 is a part of cyclic group including ethylene (—CH 2 CH 2 —), or trimethylene (—CH 2 CH 2 CH 2 —) forming cyclopentyl or cyclohexanyl group, respectively.
- R 2 , R 3 are independently hydrogen, a lower alkyl (C 1 -C 6 ) including, but not limited to methyl, hydroxymethyl, methoxymethyl, halomethyl including, but not limited to fluoromethyl, ethyl, propyl, optionally substituted ethenyl including, but not limited to vinyl, halovinyl (F—CH ⁇ C), optionally substituted ethynyl including, but not limited to haloethynyl (F—C ⁇ C), optionally substituted allyl including, but not limited to haloallyl (FHC ⁇ CH—CH 2 —); and R 4 is acyl including, but not limited to acetyl, benzoyl, arylalkyl including but not limited to
- the diol (42B) can be converted to the cyclic sulfite (IIIa) by treatment with thionyl chloride (SOCl 2 ) in presence of an alkylamine such as triethylamine, diisopropyl ethylamine, or pyridine, which can then be oxidized using the oxidants selected from a first group consisting of RuCl 3 , KMnO 4 , and TEMPO or a combination of the first group and one of the second group consisting of NaIO 4 , KIO 4 , HIO 4 , mCPBA, NaOCl, and oxone.
- SOCl 2 thionyl chloride
- the solvent of this step is selected from one or more of the group consisting of chloroform, methylene chloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, benzene, and toluene, alone or in combination with water.
- chloroform methylene chloride
- 1,2-dichloroethane diethyl ether
- tetrahydrofuran benzene
- benzene and toluene
- toluene alone or in combination with water.
- the diol 42B can be converted to the cyclic carbonate (IIIc) by treatment with carbonyl diimidazole or carbonyl dimethoxide (Scheme 8) (Chang, et al Tetrahedron Lett. 1996, 37, 3219-3222).
- the cyclic sulfate (IIIb, Scheme 8) can be converted to the fluorinated sulfate ester of the formula, 51B (Scheme 9), in high yield and with high regioselectivity and stereospecificity, by treatment with tetraalkylammonium fluoride including, but not limited to tetramethylammonium fluoride (TMAF), tetraethylammonium fluoride (TEAF), or tetrabutylammomnium fluoride (TBAF), or tris(dimethylamino)sulfur (trimethylsilyl)difluoride (TAS-F) (Fuentes J, et al Tetrahedron lett.
- TMAF tetramethylammonium fluoride
- TEAF tetraethylammonium fluoride
- TBAF tetrabutylammomnium fluoride
- TAS-F tris(dimethylamino)
- Metal fluorides such as silver fluoride (AgF), potassium fluoride (KF), cesium fluoride (CsF), or rubidium fluoride (RbF), can be used alone or with catalytic amount of tetraalkylammonium fluoride, crown-ether, diglyme, or polyethylene glycol, or other phase transfer catalyst.
- the cyclic sulfate (IIIb) can be converted to other 2-substituted sulfates of the formula MB by treatment with NaBH 4 , tetraalkylammonium chloride, tetraalkylammonium bromide, NaN 3 or LiN 3 , NH 4 OR, NH 4 SCN, CF 3 I-tetrakis(dimethylamino)-ethylene (TDAE), and tetraalkylammonium nitrate (Gao et al J. Am. Chem. Soc.
- R 2 , R 3 is independently hydrogen, a lower alkyl (C 1 -C 6 ) including, but not limited to methyl, hydroxymethyl, methoxymethyl, halomethyl including, but not limited to fluoromethyl, ethyl, propyl, optionally substituted ethenyl including, but not limited to vinyl, halovinyl (F—CH ⁇ C), optionally substituted ethynyl including, but not limited to haloethynyl (F—C ⁇ C), optionally substituted allyl including, but not limited to haloallyl (FHC ⁇ CH—CH 2 —).
- a lower alkyl C 1 -C 6
- a lower alkyl including, but not limited to methyl, hydroxymethyl, methoxymethyl, halomethyl including, but not limited to fluoromethyl, ethyl, propyl, optionally substituted ethenyl including, but not limited to vinyl, halovinyl (F—CH ⁇ C
- Nu is halogen (F, Cl, Br), N 3 , CN, NO 3 , CF 3 , SCN, OR or NR 2 where R is acyl including, but not limited to acetyl, benzoyl, arylalkyl including but not limited to benzyl, lower alkyl (C 1-10 ) including, but not limited to methyl, ethyl, propyl, CH 2 R where R is hydrogen, lower alkyl (C 1-10 ) including, but not limited to methyl, ethyl, propyl.
- R is acyl including, but not limited to acetyl, benzoyl, arylalkyl including but not limited to benzyl, lower alkyl (C 1-10 ) including, but not limited to methyl, ethyl, propyl, CH 2 R where R is hydrogen, lower alkyl (C 1-10 ) including, but not limited to methyl, ethyl, propyl.
- the protecting group includes, but is not limited to the following: trityl, t-butyldimethylsilyl, t-butyldiphenylsilyl, benzyloxymethyl, benzoyl, toluoyl, 4-phenyl benzoyl, 2-, 3-, or 4-nitrobenzoyl, 2-, 3-, or 4-chlorobenzoyl, other substituted benzoyl.
- the base includes, but is not limited to the following: imidazole, pyridine, 4-(dimethylamino)pyridine, triethyllamine, diisopropylethylamine, 1,4-diazabicyclo[2,2,2]-octane.
- the solvent includes, but is not limited to the following: pyridine, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran.
- the lactone 53B can be fully protected with appropriate protection agents with an appropriate base in an appropriate solvent.
- the protecting group (R 5 , R 6 ) includes, but is not limited to the following: methoxymethyl, methoxyethyl, benzyloxymethyl, ethoxymethyl, trityl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, acyl including acetyl, pivaloyl, benzoyl, toluoyl, 4-phenyl benzoyl, 2-, 3-, or 4-nitrobenzoyl, 2-, 3-, or 4-chlorobenzoyl, other substituted benzoyl.
- the base includes, but is not limited to the following list: imidazole, pyridine, 4-(dimethylamino)pyridine, triethyllamine, diisopropylethylamine, 1,4-diazabicyclo[2,2,2]octane.
- the solvent includes, but is not limited to pyridine, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran (Scheme 10).
- R 5 and R 6 are O-protecting groups that can be acyl or silyl or alkyl or aralkyl with C 1-20 ).
- Treatment of 54 with silylated N 4 -benzoylcytosine in the presence of TMSOTf in CHCl 3 formed an oxonium intermediate 54-i.
- Silylated base could attack 54-1 from up-side to give ⁇ -anomer 55B or from bottom to provide ⁇ -anomer 55B-alpha.
- silylated base attacked intermediate 54-i mainly from bottom (less stereohindered side) to afford a mixture of ⁇ / ⁇ -anomers with a ratio of 2/1 in favor of ⁇ -anomer.
- silylated N 4 -benzoylcytosine in the presence of SnCl 4 , a complex 54-ii was formed instead of oxonium 54-i.
- Silyated N 4 -benzoylcytosine attacked 54-ii from less stereohindered up-side to give a mixture of ⁇ / ⁇ -anomers with a ratio of 1/5 in favor of ⁇ -anomer.
- Compound 54 can be made from the protected lactone of the formula, 49B, which can be reduced with DIBAL-H or lithium tri-tert-butoxyaluminum hydride and other hydride reducing agent to the lactol, which can then converted either to the acylate by acylation with acyl halide, or acyl anhydride, in presence of an appropriate base in an appropriate solvent.
- Acyl halide or acyl anhydride includes, but is not limited to the following list: acetic chloride, optionally substituted benzoyl chloride, acetic anhydride, optionally substituted benzoyl anhydride.
- the base includes, but is not limited to the following: imidazole, pyridine, 4-(dimethylamino)pyridine, triethyllamine, diisopropylethylamine, 1,4-diazabicyclo[2,2,2]octane.
- the solvent includes, but is not limited to the following list: pyridine, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran.
- nucleosides of general structures I and II are the most preferable procedure for the synthesis of nucleosides of general structures I and II as shown in Scheme 4, Scheme 5 and Scheme 6, above through (i) synthesis of the intermediate, derivatives of 2-alkyl-4,5-di-O-protected-2,3-dihydroxy-pentanoic-acid ester of general structure I, (ii) conversion of 42B into the 3,5-protected 2-deoxy-2-fluoro-2-C-methyl-D-ribono- ⁇ -latone of general structure 49B, and (iii) conversion of 49B into purine and pyrimidine nucleosides of general structures of I and II.
- Mukaiyama et al. (Chem. Lett., 1983, 173) disclosed dihydroxylation of olefins with KMnO 4 and 18-crown-6 ether in dichloromethane at ⁇ 40° C. Attempts at dihydroxylation of 41 under Mukaiyama's conditions but at different temperatures offer a 6:1 mixture of 42 and its diastereomer in 50% yield at ⁇ 40° C. and the same mixture in 94% yield at ⁇ 10° C.
- diol 42 was found to be isolable when the corresponding 41 is treated with KMnO 4 without added alkali and crown ether.
- oxidation does not proceed even at room temperature conditions for two days. Addition of water to the mixture promotes the reaction. It is found that the more water in the reaction media the faster the reaction proceeds with poor selectivity of 42 production; the less water the slower the reaction but improved selectivity. In any case, the yield is rather poor due to further oxidation.
- Example 2 A mixture of the product of Example 2(170 mg, 0.370 mmol), trifluoroacetic acid (0.8 mL), and water (2 mL) in acetonitrile (10 mL) was heated at 80° C. for 1.5 hours, diluted with ethyl acetate (15 mL), washed with water (10 mL) and saturated sodium bicarbonate solution (10 mL). The aqueous layer was saturated with NaCl and extracted with ethyl acetate (10 mL).
- Example 3 The compound of Example 3 (60 mg, 0.16 mmol) was dissolved in anhydrous pyridine (1 mL) and benzoyl chloride (0.3 mL) was added. The resulting reaction mixture was stirred at room temperature for 20 min, water added (1 mL), stirred for 20 min, diluted with ethyl acetate (5 mL), washed with water (2 mL) and 1M HCl (2 mL ⁇ 3), and dried with sodium sulfate.
- TTAP Tetradecyltimethylammonium Permanganate
- reaction mixture is concentrated in vacuo and the residue extracted with ethyl acetate (3 ⁇ 15 mL), dried (Na 2 SO 4 ), evaporated to give a white solid, which is further dissolved in 5 mL of CH 2 Cl 2 , passed it through a plug of silica gel topped with Celite, washed with ethyl acetate (50 ml). The filtrate is dried in vacuo to give viscous oil (174 mg 71% yield) as an 8:1 mixture of which the predominant isomer is the titled compound.
- the resulting colorless mixture is filtered through a frit, and extracted the filtrate with ethyl acetate (2 ⁇ 25 ml), dried (Na 2 SO 4 ) and concentrated to give a viscous oil consisting of 10-20% of unreacted olefin starting material along with the desired diols and its isomer in a ratio of 6:1 ( 1 H NMR).
- Olefin starting material can be removed by passing through a small pad of silica gel using 5% ethyl acetate:hexane.
- a 6:1 mixture of the desired diols is eluted from the column with 20% ethyl acetate/hexane, and obtained as a white solid (200 mg ⁇ 80%) upon evaporation of the solvent.
Abstract
The present invention provides (i) processes for preparing a 2′-deoxy-2′-fluoro-2′-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2′-deoxy-2′-fluoro-2′-C-methyl-β-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
Description
- This application a continuation of U.S. patent application Ser. No. 11/225,425, filed Sep. 13, 2005, which claims the benefit of Provisional Patent Application Ser. No. 60/609,783, filed Sep. 14, 2004, Provisional Patent Application Ser. No. 60/610,035, filed Sep. 15, 2004, and Provisional Patent Application Ser. No. 60/666,230, filed Mar. 29, 2005. The entire contents of all of the above-mentioned applications are incorporated herein by reference.
- The present invention provides (i) processes for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2′-deoxy-2′-fluoro-2′-C-methyl-β-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
- HCV infection has reached epidemic levels worldwide, and has tragic effects on the infected patients. Presently there is no effective treatment for this infection and the only drugs available for treatment of chronic hepatitis C are various forms of alpha interferon (IFN-a), either alone or in combination with ribavirin. However, the therapeutic value of these treatments has been compromised largely due to adverse effects, which highlights the need for development of additional options for treatment.
- HCV is a small, enveloped virus in the Flaviviridae family, with a positive single-stranded RNA genome of ˜9.6 kb within the nucleocapsid. The genome contains a single open reading frame (ORF) encoding a polyprotein of just over 3,000 amino acids, which is cleaved to generate the mature structural and nonstructural viral proteins. ORF is flanked by 5′ and 3′ non-translated regions (NTRs) of a few hundred nucleotides in length, which are important for RNA translation and replication. The translated polyprotein contains the structural core (C) and envelope proteins (E1, E2, p7) at the N-terminus, followed by the nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B). The mature structural proteins are generated via cleavage by the host signal peptidase. The junction between NS2 and NS3 is autocatalytically cleaved by the NS2/NS3 protease, while the remaining four junctions are cleaved by the N-terminal serine protease domain of NS3 complexed with NS4A. The NS3 protein also contains the NTP-dependent helicase activity which unwinds duplex RNA during replication. The NS5B protein possesses RNA-dependent RNA polymerase (RDRP) activity, which is essential for viral replication. Unlike HBV or HIV, no DNA is involved in the replication of HCV.
- U.S. Patent Publication (US 2005/0009737 A1) discloses that 1-(2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranosyl)cytosine (14) is a potent and selective anti-HCV agent. Previously known synthetic procedures (Schemes 1-3) for this compound are quite inefficient, with very low overall yields and are not amendable to large-scale.
- Previously known methods for the preparation of (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, and its analogues, from D-xylose, cytidine, or uridine employed DAST or Deoxofluor® for the key fluorination reaction. However, DAST and Deoxofluor® are expensive, hazardous for industrial synthesis, and provide often unreliable results. Therefore, these alkylaminosulfur trifluorides are not suitable for industrial production.
- As a part of an effort to find better fluorination conditions, it has been discovered that opening of a cyclic sulfate with non-alkylaminosulfur trifluoride fluorinating agents is an excellent way to synthesize the anti-HCV nucleoside, (2′R)-2′-deoxy-2′-fluoro-2′-C-methylcytidine. In addition, it was discovered that this novel synthetic route can be adopted to other nucleosides including the anti-HCV nucleoside, D-2-deoxy-2-fluoro-cytidine (Devos, et al, U.S. Pat. No. 6,660,721), anti-HBV nucleosides, D and L-2′,3′-didehydro-2′,3′-dideoxy-2′-fluoro-nucleosides (Schinazi, et al, U.S. Pat. No. 6,348,587) (I and II, FIG. 3) as well as other 2′-substituted nucleosides such as D- and L-FMAU (Su, et al., J Med. Chem, 1986, 29, 151-154; Chu, et al., U.S. Pat. No. 6,512,107).
- What is needed is a novel and cost effective process for the synthesis of 2′-C-alkyl-2′-deoxy-2′-substituted-D-ribopyranosyl nucleosides that have activity against HCV.
- The present invention as disclosed herein relates to various intermediates and synthetic methods for the preparation of compounds of general formulas [I] and [II],
- wherein
-
- X is halogen (F, Cl, Br),
- Y is N or CH,
- Z is halogen, OH, OR′ SH, SR′, NH2, NHR′, or R′
- R2 is alkyl of C1-C3, vinyl, or ethynyl;
- R3′ and R5′ can be same or different H, alkyl, aralkyl, acyl, cyclic acetal such as 2′,3′-O-isopropylidene or 2′,3-O-benzylidene, or 2′,3′-cyclic carbonate.
- R2, R4, and R5 are independently H, halogen including F, Cl, Br, I, OH, OR′, SH, SR′, N3, NH2, NHR′, NR′2, NHC(O)OR′, lower alkyl of C1-C6, halogenated (F, Cl, Br, I) lower alkyl of C1-C6 such as CF3 and CH2CH2F, lower alkenyl of C2-C6 such as CH═CH2, halogenated (F, Cl, Br, I) lower alkenyl of C2-C6 such as CH═CHCl, CH═CHBr and CH═CHI, lower alkynyl of C2-C6 such as C═CH, halogenated (F, Cl, Br, I) lower alkynyl of C2-C6, lower alkoxy of C1-C6 such as CH2OH and CH2CH2OH, halogenated (F, Cl, Br, I) lower alkoxy of C1C6, CO2H, CO2R′, CONH2, CONHR′, CONR′2, CH═CHCO2H, CH═CHCO2R′; and,
- R′ is an optionally substituted alkyl or acyl of C1-C12 (particularly when the alkyl is an amino acid residue), cycloalkyl, optionally substituted alkynyl of C2-C6, optionally substituted lower alkenyl of C2-C6, or optionally substituted acyl.
- Presently no preventive means against Flaviviridae, including hepatitis C virus (HCV), Dengue virus (DENV), West Nile virus (WNV) or Yellow Fever virus (YFV), infection is available. The only approved therapies are for treatment of HCV infection with alpha interferon alone or in combination with the nucleoside ribavirin, but the therapeutic value of these treatments has been compromised largely due to adverse effects. It was recently discovered that a group of nucleosides, including 2′-deoxy-2′-fluoro-2′-C-methylcytidine, exhibit potent and selective activity against replication of HCV in a replicon system. However, the difficulty of chemical synthesis of this and analogous nucleosides impedes further biophysical, biochemical, pharmacological evaluations mandatory for development of clinical drugs for treatment of Flaviviridae infection.
- The present invention provides an efficient preparation of nucleosides and intermediates containing the 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranosyl moiety.
- The term “independently” is used herein to indicate that the variable, which is independently applied, varies independently from application to application. Thus, in a compound such as RaXYRa, wherein Ra is “independently carbon or nitrogen”, both Ra can be carbon, both Ra can be nitrogen, or one Ra can be carbon and the other Ra nitrogen.
- As used herein, the terms “enantiomerically pure” or “enantiomerically enriched” refers to a nucleoside composition that comprises at least approximately 95%, and preferably approximately 97%, 98%, 99% or 100% of a single enantiomer of that nucleoside.
- As used herein, the term “substantially free of” or “substantially in the absence of” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside. In a preferred embodiment, in the methods and compounds of this invention, the compounds are substantially free of enantiomers
- The term “alkyl,” as used herein, unless otherwise specified, refers to a saturated straight or branched hydrocarbon chain of typically C1 to C10, and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl, and the like. The term includes both substituted and unsubstituted alkyl groups. Alkyl groups can be optionally substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate. One or more of the hydrogen atoms attached to carbon atom on alkyl may be replaced by one or more halogen atoms, e.g. fluorine or chlorine or both, such as trifluoromethyl, difluoromethyl, fluorochloromethyl, and the like. The hydrocarbon chain may also be interrupted by a heteroatom, such as N, O or S.
- The term “lower alkyl,” as used herein, and unless otherwise specified, refers to a C1 to C4 saturated straight or branched alkyl group, including both substituted and unsubstituted forms as defined above. Unless otherwise specifically stated in this application, when alkyl is a suitable moiety, lower alkyl is preferred. Similarly, when alkyl or lower alkyl is a suitable moiety, unsubstituted alkyl or lower alkyl is preferred.
- The term “cycloalkyl”, as used herein, unless otherwise specified, refers to a saturated hydrocarbon ring having 3-8 carbon atoms, preferably, 3-6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkyl group may also be substituted on the ring by an alkyl group, such as cyclopropylmethyl and the like.
- The terms “alkylamino” or “arylamino” refer to an amino group that has one or two alkyl or aryl substituents, respectively.
- The term “protected,” as used herein and unless otherwise defined, refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis. Non-limiting examples include: C(O)-alkyl, C(O)Ph, C(O)aryl, CH3, CH2-alkyl, CH2-alkenyl, CH2Ph, CH2-aryl, CH2O-alkyl, CH2O-aryl, SO2-alkyl, SO2-aryl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, and 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).
- The term “aryl,” as used herein, and unless otherwise specified, refers to phenyl, biphenyl, or naphthyl, and preferably phenyl. The term includes both substituted and unsubstituted moieties. The aryl group can be substituted with one or more substituents, including, but not limited to hydroxyl, halo, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis,” 3rd ed., John Wiley & Sons, 1999.
- The terms “alkaryl” or “alkylaryl” refer to an alkyl group with an aryl substituent. The terms “aralkyl” or “arylalkyl” refer to an aryl group with an alkyl substituent, as for example, benzyl.
- The term “halo,” as used herein, includes chloro, bromo, iodo and fluoro.
- The term “acyl ester” or “O-linked ester” refers to a carboxylic acid ester of the formula C(O)R′ in which the non-carbonyl moiety of the ester group, R′, is a straight or branched alkyl, or cycloalkyl or lower alkyl, alkoxyalkyl including methoxymethyl, aralkyl including benzyl, aryloxyalkyl such as phenoxymethyl, aryl including phenyl optionally substituted with halogen (F, Cl, Br, I), C1 to C4 alkyl or C1 to C4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butyl silyl) or diphenylmethylsilyl. Aryl groups in the esters optimally include a phenyl group.
- The term “acyl” refers to a group of the formula R″C(O)—, wherein R″ is a straight or branched alkyl, or cycloalkyl, amino acid, aryl including phenyl, alkylaryl, aralkyl including benzyl, alkoxyalkyl including methoxymethyl, aryloxyalkyl such as phenoxymethyl; or substituted alkyl (including lower alkyl), aryl including phenyl optionally substituted with chloro, bromo, fluoro, iodo, C1 to C4 alkyl or C1 to C4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxy-trityl, substituted benzyl, alkaryl, aralkyl including benzyl, alkoxyalkyl including methoxymethyl, aryloxyalkyl such as phenoxymethyl. Aryl groups in the esters optimally comprise a phenyl group. In particular, acyl groups include acetyl, trifluoroacetyl, methylacetyl, cyclopropylacetyl, cyclopropyl carboxy, propionyl, butyryl, isobutyryl, hexanoyl, heptanoyl, octanoyl, neo-heptanoyl, phenylacetyl, 2-acetoxy-2-phenylacetyl, diphenylacetyl, α-methoxy-α-trifluoromethyl-phenylacetyl, bromoacetyl, 2-nitro-benzeneacetyl, 4-chloro-benzeneacetyl, 2-chloro-2,2-diphenylacetyl, 2-chloro-2-phenylacetyl, trimethylacetyl, chlorodifluoroacetyl, perfluoroacetyl, fluoroacetyl, bromodifluoroacetyl, methoxyacetyl, 2-thiopheneacetyl, chlorosulfonylacetyl, 3-methoxyphenylacetyl, phenoxyacetyl, tert-butylacetyl, trichloroacetyl, monochloro-acetyl, dichloroacetyl, 7H-dodecafluoro-heptanoyl, perfluoro-heptanoyl, 7H-dodeca-fluoroheptanoyl, 7-chlorododecafluoro-heptanoyl, 7-chloro-dodecafluoro-heptanoyl, 7H-dodecafluoroheptanoyl, 7H-dodeca-fluoroheptanoyl, nona-fluoro-3,6-dioxa-heptanoyl, nonafluoro-3,6-dioxaheptanoyl, perfluoroheptanoyl, methoxybenzoyl, methyl 3-amino-5-phenylthiophene-2-carboxyl, 3,6-dichloro-2-methoxy-benzoyl, 4-(1,1,2,2-tetrafluoro-ethoxy)-benzoyl, 2-bromo-propionyl, omega-aminocapryl, decanoyl, n-pentadecanoyl, stearyl, 3-cyclopentyl-propionyl, 1-benzene-carboxyl, O-acetylmandelyl, pivaloyl acetyl, 1-adamantane-carboxyl, cyclohexane-carboxyl, 2,6-pyridinedicarboxyl, cyclopropane-carboxyl, cyclobutane-carboxyl, perfluorocyclohexyl carboxyl, 4-methylbenzoyl, chloromethyl isoxazolyl carbonyl, perfluorocyclohexyl carboxyl, crotonyl, 1-methyl-1H-indazole-3-carbonyl, 2-propenyl, isovaleryl, 1-pyrrolidinecarbonyl, 4-phenylbenzoyl. When the term acyl is used, it is meant to be a specific and independent disclosure of acetyl, trifluoroacetyl, methylacetyl, cyclopropylacetyl, propionyl, butyryl, isobutyryl, hexanoyl, heptanoyl, octanoyl, neo-heptanoyl, phenylacetyl, diphenylacetyl, ct-trifluoromethyl-phenylacetyl, bromoacetyl, 4-chloro-benzeneacetyl, 2-chloro-2,2-diphenylacetyl, 2-chloro-2-phenylacetyl, trimethylacetyl, chlorodifluoroacetyl, perfluoroacetyl, fluoroacetyl, bromodifluoroacetyl, 2-thiopheneacetyl, tert-butylacetyl, trichloroacetyl, monochloro-acetyl, dichloroacetyl, methoxybenzoyl, 2-bromo-propionyl, decanoyl, n-pentadecanoyl, stearyl, 3-cyclopentyl-propionyl, 1-benzene-carboxyl, pivaloyl acetyl, 1-adamantane-carboxyl, cyclohexane-carboxyl, 2,6-pyridinedicarboxyl, cyclopropane-carboxyl, cyclobutane-carboxyl, 4-methylbenzoyl, crotonyl, 1-methyl-1H-indazole-3-carbonyl, 2-propenyl, isovaleryl, 4-phenylbenzoyl.
- The term “lower acyl” refers to an acyl group in which R″, above defined, is lower alkyl.
- The term “natural nucleic base” and “modified nucleic base” refer to “purine” or “pyrimidine” bases as defined below.
- The term “purine” or “pyrimidine” base includes, but is not limited to, adenine, N6-alkylpurines, N6-acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N6-benzylpurine, N6-halopurine, N6-vinylpurine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-allylaminopurine, N6-thioallyl purine, N6-alkylpurines, N2-alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrimidine, uracil, 5-halouracil, including 5-fluorouracil, C5-alkylpyrimidines, C5-benzylpyrimidines, C5-halopyrimidines, C5-vinylpyrimidine, C5-acetylenic pyrimidine, C5-acyl pyrimidine, N4-acetylcytosine, N4-benzoylcytosine, N4-alkyl pyrimidine, C5-hydroxyalkyl purine, C5-amidopyrimidine, C5-cyanopyrimidine, C5-iodopyrimidine, C6-iodo-pyrimidine, C5-Br-vinyl pyrimidine, C6-Br-vinyl pyrimidine, C5-nitropyrimidine, C5-amino-pyrimidine, N2-alkylpurines, N2-alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl. Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.
- The term “amino acid” includes naturally occurring and synthetic α, β γ or δ amino acids, and includes but is not limited to, amino acids found in proteins, i.e. glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. In a preferred embodiment, the amino acid is in the L-configuration. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, β-alanyl, β-valinyl, β-leucinyl, β-isoleucinyl, β-prolinyl, β-phenylalaninyl, β-tryptophanyl, β-methioninyl, β-glycinyl, β-serinyl, β-threoninyl, β-cysteinyl, β-tyrosinyl, β-asparaginyl, β-glutaminyl, β-aspartoyl, β-glutaroyl, β-lysinyl, β-argininyl or β-histidinyl. When the term amino acid is used, it is considered to be a specific and independent disclosure of each of the esters of α, βγ or δ glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine in the D and L-configurations.
- The term “pharmaceutically acceptable salt or prodrug” is used throughput the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a compound which, upon administration to a patient, provides the active compound. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. Pharmaceutically acceptable salts may also be acid addition salts when formed with a nitrogen atom. Such salts are derived from pharmaceutically acceptable inorganic or organic acids, such as hydrochloric, sulfuric, phosphoric, acetic, citric, tartaric, and the like. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
- Applicants have developed a novel, practical and efficient process for the synthesis of 2-C-alkyl-2-deoxy-2-substituted-D-ribofuranose derivatives, the key intermediates to 14 (Scheme 1) and derivatives and analogues thereof using or without using chiral catalysts. The key step in the synthesis of 14 is asymmetric conversion of 41 to 42 using chiral catalysts (Scheme 4). The previous disclosed synthesis of 42 required Sharpless AD catalysts, such as dihydroquinidine (DHQD) and derivatives. The present invention as disclosed herein relates to the stereoselective preparation of 41 to 42 using osmium, osmate or permanganate without chiral catalysts. The applicants in this present invention also develop a practical and efficient process for the synthesis of 49 from 42 by using the nucleophilic opening of the cyclic sulfate 50 (Scheme 6) in highly stereospecific and regioselective manner. The procedure depicted in Schemes 4, 5 and 6 are the current method of choice for preparative synthesis of 14 and related derivatives.
- (i) Synthesis of the Cyclic Sulfite (IIIa) and Cyclic Sulfate (IIIb)
- This invention relates to the process for the preparation of the 2′-F-nucleosides and other 2′-substituted nucleosides of the general formula IB and IB-L- by using the nucleophilic opening of the cyclic sulfite, IIIa (X═SO), sulfate, IIIb (X═SO2), of the formula, III in highly stereospecific and regioselective manner, via the lactones of the formula, IV.
- Wherein the formula IB, IB-L, III, IV has following specifications:
-
- R1 is independently a lower alkyl (C1-C6) including, but not limited to methyl, ethyl, optionally substituted phenyl, optionally substituted benzyl; alternatively R1 is a part of cyclic alkylene including ethylene (—CH2CH2—), or trimethylene (—CH2CH2CH2—) forming cyclic pentyl or cyclic hexanyl group;
- R2, R3 are independently hydrogen, a lower alkyl (C1-C6) including, but not limited to methyl, hydroxymethyl, methoxymethyl, halomethyl including, but not limited to fluoromethyl, ethyl, propyl, optionally substituted ethenyl including, but not limited to vinyl, halovinyl (F—CH═C), optionally substituted ethynyl including, but not limited to haloethynyl (F—C≡C), optionally substituted allyl including, but not limited to haloallyl (FHC═CH—CH2—);
- R4 is independently hydrogen, aryl including, but not limited to phenyl, aryl alkyl including, but not limited to benzyl, lower alkyl including, but not limited to, methyl, ethyl, propyl. Nu is halogen (F, Cl, Br), N3, CN, NO3, CF3, OR or NR where R is acyl including, but not limited to acetyl, benzoyl, arylalkyl including but not limited to benzyl, lower alkyl including, but not limited to, methyl, ethyl, propyl, CH2R where R is hydrogen, lower alkyl including, but not limited to, methyl, ethyl, propyl;
- X is SO2, SO, or CO; and
- B is a natural or modified nucleic base.
In one embodiment, formula, IB is:
- wherein,
-
- R2, R3 are independently hydrogen, a lower alkyl (C1-C6) including, but not limited to methyl, hydroxymethyl, methoxymethyl, halomethyl including, but not limited to fluoromethyl, ethyl, propyl, optionally substituted ethenyl including, but not limited to vinyl, halovinyl (F—CH═C), optionally substituted ethnyl including, but not limited to haloethnyl (F—C═C), optionally substituted allyl including, but not limited to haloallyl (FHC═CH—CH2—);
- B is a natural or modified nucleic base.
- The present invention as disclosed herein relates to processes for the synthesis of a compound, 2-alkyl-4,5-di-O-protected-2,3-dihydroxy-pentanoic-acid ester of the following general formula 42B, which is the important intermediate in the synthesis of anti-HCV nucleosides of general formulas [I] and [II] (below).
- wherein R′, R″=isopropylidene, benzylidene or cyclohexylidene or a like, or a part of cyclic group including ethylene (—CH2CH2—), or trimethylene (—CH2CH2CH2—) forming cyclopentyl or cyclohexanyl group, respectively; R′ and R″ can be independently lower alkyl of C1-C6, or aryl of C6-C20), benzyl and other optionally substituted benzyl, trialkylsilyl, t-butyl-dialkylsyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, MEM and other optionally ether protecting groups; or H, acetyl, benzoyl and other optionally substituted acyl (R′ and R″ are —C(O)—R, wherein R can be lower alkyl of C1-C6, or aryl of C6-C20, benzyl or other optionally substituted benzyl);
- R1, R2 are independently hydrogen, aryl (C6-C20) and a lower alkyl (C1-C6) including methyl, hydroxymethyl, methoxymethyl, halomethyl including fluoromethyl, ethyl, propyl, optionally substituted ethenyl including vinyl, halovinyl (F—CH═C), optionally substituted ethynyl including haloethynyl (F—C≡C), optionally substituted allyl including haloallyl (FHC═CH—CH2—); and
- R3 is independently hydrogen, aryl including phenyl, aryl alkyl including, but not limited to benzyl, lower alkyl (C1-6) including methyl, ethyl, or propyl.
- The invention as disclosed herein also relates to processes for making compounds of the following general formula 49B, which are prepared from 2-alkyl-4,5-di-O-protected-2,3-dihydroxy-pentanoic-acid ester derivatives of general formula [42B].
- wherein R3 and R5 can be independently H, CH3, Ac, Bz, pivaloyl, or 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, para-phenylbenzoyl, and other optionally substituted acyl (R3 and R5 are —C(O)—R, R can be independently lower alkyl of C1-C6, or aryl of C6-C20), benzyl, 4-methoxybenzyl and other optionally substituted benzyl (R3 and R5 can be independently aryl of C6-C20), trityl, trialkylsilyl, t-butyl-dialkylsyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, MEM and other optionally ether protecting groups (R3 and R5 can be independently alkyl of C1-C10), or R3 and R5 are linked through —SiR2—O—SiR2— or —SiR2—, wherein R is a lower alkyl group such as Me, Et, n-Pr or i-Pr.
- wherein
-
- X is halogen (F, Cl, Br),
- Y is N or CH,
- Z is, halogen, OH, OR′, SH, SR′, NH2, NHR′, or R′
- R2′ is alkyl of C1-C3, vinyl, or ethynyl
- R3′ and R5′ can be same or different H, alkyl, aralkyl, acyl, cyclic acetal such as 2′,3′-O-isopropylidene or 2′,3-O-benzylidene, or 2′,3′-cyclic carbonate.
- R2, R4, R5 and R6 are independently H, halogen including F, Cl, Br, I, OH, OR′, SH, SR′, N3, NH2, NHR′, NR″, NHC(O)OR′, lower alkyl of C1-C6, halogenated (F, Cl, Br, I) lower alkyl of C1-C6 such as CF3 and CH2CH2F, lower alkenyl of C2-C6 such as CH═CH2, halogenated (F, Cl, Br, I) lower alkenyl of C2-C6 such as CH═CHCl, CH═CHBr and CH═CHI, lower alkynyl of C2-C6 such as C═CH, halogenated (F, Cl, Br, I) lower alkynyl of C2-C6, lower alkoxy of C1-C6 such as CH2OH and CH2CH2OH, halogenated (F, Cl, Br, I) lower alkoxy of C1-C6, CO2H, CO2R′, CONH2, CONHR′, CONR′2, CH═CHCO2H, CH═CHCO2R′; and,
- R′ and R″ are the same or different and are optionally substituted alkyl of C1-C12 (particularly when the alkyl is an amino acid residue), cycloalkyl, optionally substituted alkynyl of C2-C6, optionally substituted lower alkenyl of C2-C6, or optionally substituted acyl.
- The reaction of the cyclic sulfate ester, 50 (Scheme 6) with tetraethylammonium fluoride or tetramethylammonium fluoride 51 (Scheme 6) quantitatively generated the fluorinated sulfate, in highly stereospecific and regioselective manner. Following acid catalyzed cyclization afforded the 2-fluoro-2-C-methyl-γ-ribonolactone, 53 in high yield. The present invention is based on this discovery and provides a process for the preparation of the 2′-deoxy-2′-substituted nucleosides, I and II, using the reactions described herein.
- (2S,3R,4R)-4,5-O-alkylidene-2-dimethyl-2,3,4,5-tetrahydroxy-2-methyl-1-pentanoic acid ethyl ester (42B), can be prepared by asymmetric dihydroxylation (AD) or stereoselective dihydroxylation of the Wittig product 41 with or without chiral catalysts. Wittig product 41, in turn, can be prepared readily from the protected (R) glyceraldehyde (Schemes 7, 8), where R1 is independently a lower alkyl (C1-C6) including, but not limited to methyl, ethyl, optionally substituted phenyl, optionally substituted benzyl. Or R1 is a part of cyclic group including ethylene (—CH2CH2—), or trimethylene (—CH2CH2CH2—) forming cyclopentyl or cyclohexanyl group, respectively. R2, R3 are independently hydrogen, a lower alkyl (C1-C6) including, but not limited to methyl, hydroxymethyl, methoxymethyl, halomethyl including, but not limited to fluoromethyl, ethyl, propyl, optionally substituted ethenyl including, but not limited to vinyl, halovinyl (F—CH═C), optionally substituted ethynyl including, but not limited to haloethynyl (F—C≡C), optionally substituted allyl including, but not limited to haloallyl (FHC═CH—CH2—); and R4 is acyl including, but not limited to acetyl, benzoyl, arylalkyl including but not limited to benzyl, lower alkyl (C1-10) including, but not limited to, methyl, ethyl, propyl, CH2R where R is hydrogen, lower alkyl (C1-10) including, but not limited to, methyl, ethyl, propyl.
- The diol (42B) can be converted to the cyclic sulfite (IIIa) by treatment with thionyl chloride (SOCl2) in presence of an alkylamine such as triethylamine, diisopropyl ethylamine, or pyridine, which can then be oxidized using the oxidants selected from a first group consisting of RuCl3, KMnO4, and TEMPO or a combination of the first group and one of the second group consisting of NaIO4, KIO4, HIO4, mCPBA, NaOCl, and oxone. The solvent of this step is selected from one or more of the group consisting of chloroform, methylene chloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, benzene, and toluene, alone or in combination with water. (Gao Y et al J. Am. Chem. Soc. 1988, 110, 7538-7539, Berridge et al J. Org. Chem. 1990, 55, 1211-1217). It is also possible that the diol is directly converted to the cyclic sulfate (IIIb) by treatment with sulfurylchloride, or sulfuryl diimidazole. On the other hand, the diol 42B can be converted to the cyclic carbonate (IIIc) by treatment with carbonyl diimidazole or carbonyl dimethoxide (Scheme 8) (Chang, et al Tetrahedron Lett. 1996, 37, 3219-3222).
- (ii) Synthesis of the Substituted 2-deoxy-D-ribono-γ-lactone, 53B
- The cyclic sulfate (IIIb, Scheme 8) can be converted to the fluorinated sulfate ester of the formula, 51B (Scheme 9), in high yield and with high regioselectivity and stereospecificity, by treatment with tetraalkylammonium fluoride including, but not limited to tetramethylammonium fluoride (TMAF), tetraethylammonium fluoride (TEAF), or tetrabutylammomnium fluoride (TBAF), or tris(dimethylamino)sulfur (trimethylsilyl)difluoride (TAS-F) (Fuentes J, et al Tetrahedron lett. 1998, 39, 7149-7152) in an aprotic polar solvent such as acetone, tetrahydrofuran, N,N-dimethylformamide, or acetonitrile (Scheme 9). Metal fluorides such as silver fluoride (AgF), potassium fluoride (KF), cesium fluoride (CsF), or rubidium fluoride (RbF), can be used alone or with catalytic amount of tetraalkylammonium fluoride, crown-ether, diglyme, or polyethylene glycol, or other phase transfer catalyst.
- The cyclic sulfate (IIIb) can be converted to other 2-substituted sulfates of the formula MB by treatment with NaBH4, tetraalkylammonium chloride, tetraalkylammonium bromide, NaN3 or LiN3, NH4OR, NH4SCN, CF3I-tetrakis(dimethylamino)-ethylene (TDAE), and tetraalkylammonium nitrate (Gao et al J. Am. Chem. Soc. 1988, 110, 7538-7539), KCN, LiCu(R)2 where R is methyl, ethyl, ethylenyl, or ethnyl. Similarly, the cyclicsulfite (IIIa) can be converted to the substituted ester 52B (Chang et al. Tetrahedron Lett. 1996, 37, 3219-3222). Then compounds of the formula 51B and 52B can be converted to the substituted lactones of the formula 53B by treatment with an acid in H2O-containing organic solvent such as methanol, ethanol, or acetonitrile.
- In Formula 53B, R2, R3 is independently hydrogen, a lower alkyl (C1-C6) including, but not limited to methyl, hydroxymethyl, methoxymethyl, halomethyl including, but not limited to fluoromethyl, ethyl, propyl, optionally substituted ethenyl including, but not limited to vinyl, halovinyl (F—CH═C), optionally substituted ethynyl including, but not limited to haloethynyl (F—C≡C), optionally substituted allyl including, but not limited to haloallyl (FHC═CH—CH2—). Nu is halogen (F, Cl, Br), N3, CN, NO3, CF3, SCN, OR or NR2 where R is acyl including, but not limited to acetyl, benzoyl, arylalkyl including but not limited to benzyl, lower alkyl (C1-10) including, but not limited to methyl, ethyl, propyl, CH2R where R is hydrogen, lower alkyl (C1-10) including, but not limited to methyl, ethyl, propyl.
- (iii) The Protection of the D-ribono-γ-lactone, 53B
- 53B can be selectively protected with appropriate protection agents to the 5-protected lactones of the formula 53C with an appropriate base in an appropriate solvent. The protecting group includes, but is not limited to the following: trityl, t-butyldimethylsilyl, t-butyldiphenylsilyl, benzyloxymethyl, benzoyl, toluoyl, 4-phenyl benzoyl, 2-, 3-, or 4-nitrobenzoyl, 2-, 3-, or 4-chlorobenzoyl, other substituted benzoyl. The base includes, but is not limited to the following: imidazole, pyridine, 4-(dimethylamino)pyridine, triethyllamine, diisopropylethylamine, 1,4-diazabicyclo[2,2,2]-octane. The solvent includes, but is not limited to the following: pyridine, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran.
- Alternatively, the lactone 53B can be fully protected with appropriate protection agents with an appropriate base in an appropriate solvent. The protecting group (R5, R6) includes, but is not limited to the following: methoxymethyl, methoxyethyl, benzyloxymethyl, ethoxymethyl, trityl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, acyl including acetyl, pivaloyl, benzoyl, toluoyl, 4-phenyl benzoyl, 2-, 3-, or 4-nitrobenzoyl, 2-, 3-, or 4-chlorobenzoyl, other substituted benzoyl. The base includes, but is not limited to the following list: imidazole, pyridine, 4-(dimethylamino)pyridine, triethyllamine, diisopropylethylamine, 1,4-diazabicyclo[2,2,2]octane. The solvent includes, but is not limited to pyridine, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran (Scheme 10).
- (ii) Complexation Directed β-glycosylation
- Coupling of 2-deoxy-2-fluoro-2-C-methyl-ribofuranoside (54: Nu=F, R3=Me, R5═R6=pivaloyl) with silylated 1V4-benzoylcytosine in the presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in CHCl3 gave a mixture of α/β-anomers with a ratio of 2/1 in favor of a-isomer. However, β-anomer was obtained as major product (α/β=1/4.9) in the same reaction catalyzed by SnCl4 under similar conditions. Possible mechanisms are proposed in Scheme 10A (R5 and R6 are O-protecting groups that can be acyl or silyl or alkyl or aralkyl with C1-20). Treatment of 54 with silylated N4-benzoylcytosine in the presence of TMSOTf in CHCl3 formed an oxonium intermediate 54-i. Silylated base could attack 54-1 from up-side to give β-anomer 55B or from bottom to provide α-anomer 55B-alpha. Because of stereohinderance at up-side caused by 2-methyl group, silylated base attacked intermediate 54-i mainly from bottom (less stereohindered side) to afford a mixture of α/β-anomers with a ratio of 2/1 in favor of α-anomer. While treatment of 54 with silylated N4-benzoylcytosine in the presence of SnCl4, a complex 54-ii was formed instead of oxonium 54-i. Silyated N4-benzoylcytosine attacked 54-ii from less stereohindered up-side to give a mixture of α/β-anomers with a ratio of 1/5 in favor of β-anomer.
- Compound 54 can be made from the protected lactone of the formula, 49B, which can be reduced with DIBAL-H or lithium tri-tert-butoxyaluminum hydride and other hydride reducing agent to the lactol, which can then converted either to the acylate by acylation with acyl halide, or acyl anhydride, in presence of an appropriate base in an appropriate solvent. Acyl halide or acyl anhydride includes, but is not limited to the following list: acetic chloride, optionally substituted benzoyl chloride, acetic anhydride, optionally substituted benzoyl anhydride. The base includes, but is not limited to the following: imidazole, pyridine, 4-(dimethylamino)pyridine, triethyllamine, diisopropylethylamine, 1,4-diazabicyclo[2,2,2]octane. The solvent includes, but is not limited to the following list: pyridine, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran.
- (iii) Synthesis of the L-nucleosides, IB-L
- The processes for the D-series of the formula I and II can be used for preparation of the L-nucleosides of the formula, IB-L from the (S)-glyceraldehydes (Scheme 11).
- (iv) Synthesis of 2-alkyl-4,5-di-O-protected-2,3-dihydroxy-pentanoic acid
- Currently, the most preferable procedure for the synthesis of nucleosides of general structures I and II is the preparation of a derivative of the 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranosyl moiety of I and II as shown in Scheme 4, Scheme 5 and Scheme 6, above through (i) synthesis of the intermediate, derivatives of 2-alkyl-4,5-di-O-protected-2,3-dihydroxy-pentanoic-acid ester of general structure I, (ii) conversion of 42B into the 3,5-protected 2-deoxy-2-fluoro-2-C-methyl-D-ribono-γ-latone of general structure 49B, and (iii) conversion of 49B into purine and pyrimidine nucleosides of general structures of I and II. The key step in Scheme 4 is the stereoselective osmium catalyzed dihydroxylation of olefinic intermediate 41 into 42 in the presence of the expensive Sharpless AD catalyst. Instead of the Sharpless catalyst, if other chiral compounds such as L-quinidine are used, the reaction also goes smoothly giving the desired 42. Kishi et al. have proposed that in OsO4 dihydroxylation of allylic alcohol derivatives (esters, ethers, acetals or ketals), the major course of reaction would occur on the face of the olefinic bond opposite to that of the preexisting hydroxyl or alkoxyl group, (Tetrahedron Lett, 1983, 24, 3943). Some examples are shown in Scheme 12 (Tetrahedron Lett, 1983, 24, 3947). In every case, the major product arose from addition of OSO4 from the anti side of the oxygen on the neighboring secondary carbon. However, stereoselectivity is not high enough for preparative synthesis.
- Encouraged by Kishi's rule, which presents that the stereochemistry is formulated as arising from the preferential approach of osmium tetroxide to occur on the face of the olefinic bond opposite to that of the preexisting hydroxyl or alkoxyl group, dihydroxylations of 41 under the original conditions but without any chiral catalysts, including Sharpless AD catalyst, were conducted. Dihydroxylation of 41 using Ke3Fe(CN)6/K2OsO2(OH)4/K2CO3 system without chiral catalysts gives the product in 77% yield, which product is a 5:1 mixture of isomers with the predominant isomer being the desired 42. The reaction of olefin 41 with OsO4 using N-methylmorpholine N-oxide (NMO) as the oxidant without chiral catalysts gave a 5:1 mixture of 42 and its isomer in 79% yield. Most surprisingly, when t-butylhydroperoxide (TBHP) is used as oxidant in the presence of catalytic amount of OSO4 in acetone and ammonium acetate as buffer (the reagent combination was used in the synthesis of alditols by Masamune and Sharpless (J. Org. Chem, 1982, 47, 1373)), the crystalline product isolated is the virtually pure desired 42. This procedure is therefore far superior to the OSO4/NMO and Fe(CN)6 3− methods. At 10 molar scale, the desired diol 42 is formed exclusively, and is isolated in 87% yield. No contamination by the other isomer was detected in this product by vigorous 1H NMR analyses.
- It is well known that in OSO4 oxidation the intermediate is cyclic osmate V (below) (Criegee, Liebigs Ann. Chem., 1936, 522, 75). cis-Dihydroxylation of olefins with potassium permanganate in alkaline media has been known for quite some time (Robinson and Robinson, J. Chem. Soc., 1925, 127, 1628), and this reaction appears to proceed through a cyclic ester VI. Thus attempts at permanganate dihydroxylation have been performed.
- Previous reports have indicated that permanganate dihydroxylation of olefins in acid or neutral conditions causes over-oxidation of the initial diol products with concomitant production of ketones and carboxylates. Only in alkaline conditions further oxidation of the diol products can be decelerated. As 41 is a carboxylic ester the reaction cannot be done in aqueous alkali. Hazra et al. (J. Chem. Soc. Perkin Trans. I, 1994, 1667) describes successful dihydroxylation of highly substituted olefins to the corresponding diols using tetradecyltrimethylammonium permanganate (TDTAP) in a mixture of t-BuOH, dichloromethane and water in the presence of 0.1 equivalent of KOH. Application of this method to dihydroxylation of 41 results in rapid formation (within 10 minutes at room temperature) of a mixture of 42 and its diastereomer in an 8:1 ratio, which is isolated in 71% yield. Oxidation occurs much faster in similar reactions without KOH, but the yield of 42 is not improved.
- Mukaiyama et al. (Chem. Lett., 1983, 173) disclosed dihydroxylation of olefins with KMnO4 and 18-crown-6 ether in dichloromethane at −40° C. Attempts at dihydroxylation of 41 under Mukaiyama's conditions but at different temperatures offer a 6:1 mixture of 42 and its diastereomer in 50% yield at −40° C. and the same mixture in 94% yield at −10° C.
- Surprisingly, in contrast to the teaching of the prior of art which discloses that oxidation of a double bond with KMnO4 proceeds via diol wherein the resultant diol is rapidly oxidized further without the presence of base, diol 42 was found to be isolable when the corresponding 41 is treated with KMnO4 without added alkali and crown ether. In pure t-butanol, oxidation does not proceed even at room temperature conditions for two days. Addition of water to the mixture promotes the reaction. It is found that the more water in the reaction media the faster the reaction proceeds with poor selectivity of 42 production; the less water the slower the reaction but improved selectivity. In any case, the yield is rather poor due to further oxidation.
- Most surprisingly, and in contradiction to the prior art, treatment of 41 with KMnO4 in acetone is found to give a 10:1 mixture in quantitative yield, the desired 42 being the major component. The stereoselectivity is found to be improved by performing the reaction in a mixture of acetone and pyridine.
- The following Examples are set forth to aid in an understanding of the invention. This section is not intended to, and should not be interpreted to, limit in any way the invention set forth in the claims which follow thereafter.
- To a solution of (2S,3R,4R)-4,5-O-isopropylidene-2,3,4,5-tetrahydroxy-2-methyl-pentanoic acid ethyl ester (R1═CH3, R2═H, R3═CH3) (2.0 g, 8.06 mmol) in anhydrous methylene chloride (40 mL) containing triethyl amine (3.4 mL) was added at 0° C. thionyl chloride (0.88 mL, 12.08 mmol) dropwise over 10 min. The resulting reaction mixture was stirred at 0° C. for 10 min, diluted with cold ether (100 mL), washed with water (50 mL×2) and brine (50 mL×2), dried with sodium sulfate, and concentrated to give a residue (IIIa, R1═CH3, R2═H, R3═CH3) which was dissolved in acetonitrile-tetrachloromethane (10:10 mL). To the obtained solution was added at room temperature sodium periodate (2.58 g, 12.06 mmol), ruthenium trichloride (16 mg, 0.077 mmol), and water (14 mL) subsequently. The resulting reaction mixture was stirred at room temperature for 10 min, diluted ether (100 mL), washed with water (50 mL×2), saturated sodium bicarbonate solution (50 mL×2), and brine (50 mL×2), dried with sodium sulfate, concentrated, and co-evaporated with toluene (30 mL×3) to a syrupy residue, the sulfate IIIb (2.23 g, 89%) which was used for the next reaction without further purification. 1H NMR (CDCl3) δ (ppm) 5.04 (d, 1H, J=9.6 Hz, H-3), 4.37 (m, 1H, H-4), 4.29 (q, 2H, J=7.6 Hz, CH 2CH3), 4.17 (dd, 1H, J=5.6, 9.6 Hz, H-5), 4.05 (dd, 1H, J=3.2, 9.6 Hz, H-5′), 1.8 (s, 3H, CH3-2), 1.38 (s, 3H, (CH 3)2C), 1.32 (t, 3H, J=6.8 Hz, CH2CH 3), 1.31 (s, 3H, (CH 3)2C).
- Method 1: To a solution of the sulfate IIIb from Example 1 (628 mg, 2.02 mmol) in anhydrous tetrahydrofuran was added at 0° C. tetrabutylammonium fluoride (1M in tetrahydrofuran, dried with 4 Å molecular sieves) dropwise over 5 min. The resulting reaction mixture was stirred at 0° C. for 20 min, another 2 m L of tetrabutylammonium fluoride (1M in tetrahydrofuran, dried with 4 Å molecular sieves, 3 mL) was added, and then the reaction mixture was stirred at 0° C. for 2 hours, then concentrated, and purified by silica gel column chromatography (EtOAc) to give to the fluorinated sulfate, as a syrup (350 mg, 38%). 1H NMR (CDCl3) δ (ppm) 4.66 (dd, 1H, J=9.6, 25.6 Hz, H-3), 4.48 (dd, 1H, J=5.2, 8.8 Hz, H-4), 4.20, 4.07 (2 m, 4H, H-5, OCH 2CH3), 3.21 (m, 8H, N(CH 2CH2CH2CH3)4), 1.69 (d, 3H, J=22.4 Hz, CH3-2), 1.59 (m, 8H, N(CH2CH 2CH2CH3)4), 1.39 (m, 8H, CH2CH2CH 2CH3)4), 1.27-1.25 (m, 9H, OCH2CH 3, (CH 3)2C), 0.96 (t, 12H, J=6.8 Hz, CH2CH2CH2CH 3)4.
- Method 2: To a solution of the cyclic sulfate IIIb (480 mg, 1.55 mmol) in anhydrous tetrahydrofuran was added at 0° C. tetrabutylammonium fluoride (1M in tetrahydrofuran, neutralized with HF-pyridine, 3.1 mL) dropwise over 5 min. The resulting reaction mixture was stirred for 39 hours, concentrated, and purified by silica gel column chromatography (CH2Cl2:MeOH=10:1) to the fluorinated sulfate as a syrup (280 mg, 39%).
- A mixture of the product of Example 2(170 mg, 0.370 mmol), trifluoroacetic acid (0.8 mL), and water (2 mL) in acetonitrile (10 mL) was heated at 80° C. for 1.5 hours, diluted with ethyl acetate (15 mL), washed with water (10 mL) and saturated sodium bicarbonate solution (10 mL). The aqueous layer was saturated with NaCl and extracted with ethyl acetate (10 mL). The combined organic layer was dried with sodium sulfate, filtered, and concentrated to give a residue, which was purified by silica gel column chromatography (hexanes:ethyl acetate=1:1 to CH2Cl2:MeOH=20:1) to give the desired compound as a white solid (60 mg, 100%). 1H NMR (CDCl3) δ (ppm) 6.06 (d, 1H, J=6.8 Hz, HO-3), 5.16 (t, 1H, J=4.8 Hz, HO-5), 4.26 (m, 1H, H-4), 3.98 (ddd, 1H, J=7.2, 8.0, 23.2 Hz, H-3), 3.78 (ddd, 1H, J=2.0, 5.2, 12.8 Hz, H-5), 3.55 (ddd, 1H, J=4.4, 5.6, 12.4 Hz, H-5′), 1.48 (d, 3H, J=24 Hz, CH3-2); 13C NMR (CDCl3) δ (ppm) 171.2 (d, J=21.2 Hz, C-1), 92.5 (d, J=177.5 Hz, C-2), 83.37 (C-4), 70.2 (d, J=15.9 Hz, C-3), 59.0 (C-5), 17.1 (d, J=25.0 Hz, CH3—C-2).
- The compound of Example 3 (60 mg, 0.16 mmol) was dissolved in anhydrous pyridine (1 mL) and benzoyl chloride (0.3 mL) was added. The resulting reaction mixture was stirred at room temperature for 20 min, water added (1 mL), stirred for 20 min, diluted with ethyl acetate (5 mL), washed with water (2 mL) and 1M HCl (2 mL×3), and dried with sodium sulfate. Upon filtration and concentration, the residue was purified by silica gel column chromatography (hexanes:ethyl acetate=10:1) to give 3,5-di-O-benzoyl-2-deoxy-2-fluoro-D-ribono-γ-lactone as a white solid (118 mg, 87%). 1H NMR (CDCl3) δ (ppm) 8.08 (m, 2H, aromatic), 7.99 (m, 2H, aromatic), 7.63 (m, 1H, aromatic), 7.58 (m, 1H, aromatic), 7.49 (m, 2H, aromatic), 7.43 (m, 2H, aromatic), 5.51 (dd, 1H, J=7.2, 17.6 Hz, H-3), 5.00 (m, 1H, H-4), 4.78 (dd, 1H, J=3.6, 12.8 Hz, H-5), 4.59 (dd, 1H, J=5.2, 12.8 Hz, H-5′), 1.75 (d, 3H, J=23.6 Hz, CH3-2)
- Method 1. To a solution of the sulfate IIIb (Scheme 9) (1.96 g, 6.32 mmol) in anhydrous N,N-dimethylformamide (20 mL) was added at 0° C. tetraethylammonium fluoride hydrate (1.39 g, 9.13 mmol) in one portion. The resulting reaction mixture was stirred for 30 min, concentrated, and co-evaporated with toluene to give a semi-solid (51b) (3.35 g, crude, proton NMR showed virtually one product). 1H NMR (CDCl3) δ (ppm) 4.61 (dd, 1H, J=9.2, 25.6 Hz, H-3), 4.51 (dd, 1H, J=5.2, 9.2 Hz, H-4), 4.23-4.05 (m, 4H, H-5, OCH 2CH3), 3.32 (q, 8H, J=7.2 Hz, N(CH 2CH3)4), 1.69 (d, 3H, J=23.2 Hz, CH3-2), 1.31-1.24 (m, 21H, OCH2CH 3, (CH 3)2C, N(CH2CH 3)4.
- Method 2: To a solution of the sulfate IIIb (148 mg, 0.477 mmol) in anhydrous acetonitrile (2 mL) was added at 0° C. tetraethylammonium fluoride hydrate (107 mg, 0.717 mmol) in one portion. The resulting reaction mixture was stirred for 24 hours, concentrated, and co-evaporated with toluene to give a semi-solid (257 mg, crude, proton NMR showed virtually one product).
- To a solution of 49B, (Scheme 6) (Nu=F, R2—H, R3=Me, R5═R6=pivaloyl, 3.44 g, 10.36 mmol) in THF (70 mL) was added LiAl(t-BuO)3H (13.47 mmol, 1M in THF, 13.47 mL) at −20° C. to −10° C. and the resulting solution was stirred at −10° C. to −15° C. for 2 h. To the solution was added an additional LiAl (t-BuO)3H (1.35 mL, 1.35 mmol) and the solution was stirred at −10° C. for 1 h. Ice water (50 mL) was added. The mixture was extracted with EtOAc (200 mL), and the organic layer was washed with water, brine and dried (Na2SO4). Solvent was removed to give crude lactol which was dissolved in CH2Cl2 (50 mL). To the solution were added Et3N (31.08 mmol, 4.24 mL), 4-dimethylaminopyridine (1 mmol, 122 mg) and trimethylacetyl chloride (20.7 mmol, 2.55 mL), and the mixture was stirred at room temperature for 16 h. Water (20 mL) was added, and the resulting mixture was stirred at room temperature for 10 min. EtOAc (200 mL) was added, and organic solution was washed with water, brine, and dried (Na2SO4). Solvent was removed and the residue was co-evaporated with toluene (2×20 mL) to give a crude intermediate (5, 6.74 g) for the next coupling reaction without purification.
- A suspension of N4-benzoylcytosine (6.06 mmol, 1.30 g) and (NH4)2SO4 (30 mmg) in HMDS (16.7 mL) was refluxed for 5 h, and the clear solution was concentrated to dryness under reduced pressure. The residue was dissolved in 1,2-dichloroethane (50 mL). To the solution were added crude 54 (1.96 g, Scheme 6) and SnCl4 (1.42 mL, 12.12 mmol) at room temperature. The solution was refluxed for 24 h. and cooled to 0° C. To the solution were added NaHCO3 (6.11 g, 72.72 mmol) and EtOAc (50 mL). To the mixture was added H2O (2 mL) slowly, and the resulting mixture was stirred at room temperature for 20 min. Solid was removed by filtration. The organic solution was washed with water, brine and dried (Na2SO4). Solvent was removed to give syrup as crude mixture of β/α-anomers with a ratio of 4/1 in favor to β-isomer. The crude product was dissolved in MeOH (1 mL) at 50° C. To the solution was added hexanes (10 mL). The mixture was allowed to stay at room temperature for 1 h, then 0° C. for 2 h. Crystals were collected by filtration, washed with hexanes to give product 55, Scheme 6 (323 mg, 20.3% from 49). Mother liquor was concentrated to dryness and purified by column chromatography (20-50% EtOAc in hexanes) to give second crop of 55. H-NMR (CDCl3): δ 8.82 (br s, 1H, NH), 8.10, 7.89, 7.62, 7.52 (m, 7H, H-5, H-6, 5 Ph-H), 6.41 (d, J=18.4 Hz, 1H, H-1′), 5.10 (m, 1H, H-3′), 4.45 (d, J=9.6 Hz, 1H, H-4′), 4.36 (t, J=2.8 Hz, 2H, H-5′), 1.35 (d, J=22.0 Hz, 3H, Me), 1.29, 1.23 [ss, 18H, C(Me)3].
- To a stirred solution of compound 41 (214 mg, 0.1 mmol) in t-BuOH under argon was added a solution of 4-methylmorpholine N-oxide (0.47 mL, 50 wt % solution in H2O) and water (0.2 mL). A 2.5 wt % solution of osmium tetraoxide in tert-butyl alcohol (0.51 mL) is added, and the mixture is stirred for 5 h at room temperature in a water bath. The mixture is evaporated in vacuo to a syrup, which is azeotroped with H2O (3×10 mL) to remove 4-methylmorpholine. The residue is dried by addition and evaporation of EtOH (2×10 mL) to give a residue, which was purified by silica gel column chromatography with 20% EtOAc in hexanes to provide the desired product and its isomer (196 mg, 79%) as a solid. Proton NMR indicates that the ratio of the desired product to its isomer is around 5:1. Recrystallization of the mixture from hexanes/ethyl acetate gives pure product (91 mg, 37.4% from starting material) as a crystalline solid. 1H NMR (DMSO-d6) δ 1.18 (t, J=7.2 Hz, 3H, —OCH2 CH 3), 1.24 (s, 3H, CH3), 1.25 (s, 3H, CH3), 1.28 (s, 3H, 2-CH3), 3.67 (t, J=7.2 Hz, 1H), 3.85, 4.06 and 4.12 (m, 4H), 4.97 (s, 1H, 2-OH, D2O exchangeable), 5.14 (d, J=7.6 Hz, 2-OH, D2O exchangeable).
- A 100 mL round-bottomed flask, equipped with a magnetic stirrer, is charged with 5 mL of tert-butyl alcohol, 5 mL of water, and a mixture of K3Fe(CN)6 (0.98 g), K2CO3 (0.41 g), and K2OsO2(OH)4 (3.2 mg). Stirring at room temperature produced two clear phases; the lower aqueous phase appears bright yellow. Methanesulfonamide (95 mg) is added at this point. The mixture is cooled to 0° C. whereupon some of salts precipitate out, 214 mg (1 mmol) of the compound 41 is added at once, and the heterogeneous slurry is stirred vigorously at 0° C. for 24 h. To the mixture is added solid sodium sulfite (1.5 g) while stirring at 0° C., and then the mixture is allowed to warm to room temperature and stirred for 30-60 min. Ethyl acetate (10 mL) is added, and after separation of the layers, the aqueous phase is further extracted with EtOAc. The organic layer is dried over Na2SO4 and concentrated to dryness. The residue is purified by silica gel column chromatography with 20% EtOAc in hexanes to provide the product (190 mg, 77%) as a solid, proton NMR indicates that the ratio of the desired product to its isomer is around 5:1. Recrystallization of the mixture with hexanes/ethyl acetate gave pure diol product (102 mg, 41% from starting material) as a crystalline solid. The 1H NMR spectrum of this product is identical to that of an authentic specimen.
- A 50 mL of flask, equipped with magnetic stirrer, is charged with 2 mL of acetone, 214 mg (1 mmol) of compound 41, 65 mg of Et4NOAc.4H2O, and 0.3 mL of tert-butyl hydroperoxide (5˜6 M in decane). After stirring at room temperature until the Et4NOAc a clear solution is obtained, the resulting solution is cooled in an ice bath and 5 mL of OSO4 (2.5 wt % in t-BuOH) is added in one portion. The solution immediately becomes brownish purple. After 1 h the ice bath is removed and the reaction mixture is allowed to warm to room temperature and stirred for 14 h. The rest of the procedure is done exactly the same way as described above. After flash column chromatography, 178 mg (72%) of product is obtained as a solid. In an expanded 1H NMR, a tiny bump is observed at δ 1.26 indicating the presence of an isomer in less than 4% in the product.
- A 250 mL of flask, equipped with magnetic stirrer, is charged with 20 mL of acetone, 2.14 g (10 mmol) of compound 41, 650 mg of Et4NOAc.4H2O, and 3 mL of tert-butyl hydroperoxide (5˜6 M in decane). After stirring at room temperature until the Et4NOAc has dissolved, the resulting solution is cooled in an ice bath and 5 mL of OsO4 (2.5 wt % in t-BuOH) is added in one portion. The solution immediately becomes brownish purple. The reaction mixture is then stirred at 0° C. for 6.5 h (monitored by TLC, hexanes:ethyl acetate=4:1, Rf=0.18). Ether (40 mL) is added at 0° C. and the resulting mixture is treated with 5 mL of freshly prepared 10% NaHSO3 solution in one portion. The ice bath is removed and stirring is continued for 1 h. EtOAc (100 mL) and H2O (50 mL) are added to the mixture. After separation of the layers, the aqueous phase is further extracted with EtOAc. The organic layer is washed with brine, dried (MgSO4) and concentrated. The residue is purified by a flash silica gel column chromatography with 20% EtOAc in hexanes to provide the product (2.16 g, 87%) as a solid. No contamination of an isomer is detected in this product by vigorous 1H NMR analyses.
- To a stirred solution of compound 41 (214 mg, 1 mmol), in t-BuOH (10 mL) and CH2Cl2 (2 mL) at room temperature is added a solution of KOH (6 mg, 0.1 mmol) in water followed by TDTAP (0.420 g, 1.12 mmol) in small portions over a period of five minutes. TLC after 5 minutes showed that the reaction is complete. The solution is quenched by using 10 mL of saturated sodium bisulfite. The reaction mixture is concentrated in vacuo and the residue extracted with ethyl acetate (3×15 mL), dried (Na2SO4), evaporated to give a white solid, which is further dissolved in 5 mL of CH2Cl2, passed it through a plug of silica gel topped with Celite, washed with ethyl acetate (50 ml). The filtrate is dried in vacuo to give viscous oil (174 mg 71% yield) as an 8:1 mixture of which the predominant isomer is the titled compound.
- To a solution of compound 41 (214 mg, 1 mmol) in CH2Cl2 (10 mL) and 18-crown-6-ether (37.5 mg, 0.1 mmol) is added KMnO4 (158 mg, 1 mmol) in portions at −40° C., and the mixture stirred for 2 h at the same temperature. During this time the reaction mixture turns to dark brown. After the reaction was complete, mixture is quenched with saturated solution of sodium bisulfite (10 mL). The resulting colorless mixture is filtered through a frit, and extracted the filtrate with ethyl acetate (2×25 ml), dried (Na2SO4) and concentrated to give a viscous oil consisting of 10-20% of unreacted olefin starting material along with the desired diols and its isomer in a ratio of 6:1 (1H NMR). Olefin starting material can be removed by passing through a small pad of silica gel using 5% ethyl acetate:hexane. A 6:1 mixture of the desired diols is eluted from the column with 20% ethyl acetate/hexane, and obtained as a white solid (200 mg˜80%) upon evaporation of the solvent.
- To a solution of compound 41 (214 mg, 1 mmol) in CH2Cl2 (10 ml) is added 37.5 mg (0.1 mmol) of 18-crown-6-ether, and mixture is cooled to −10° C. KMnO4 (237 mg, 1.5 mmol) is added in portions, and the mixture stirred at −10° C. for 2 h. During this time the reaction mixture turns to dark brown, which is treated with saturated solution of sodium bisulfite (10 mL). The resulting mixture is filtered through a frit, and the filtrate is extracted with ethyl acetate (2×25 ml), dried (Na2SO4) and evaporated to give a white solid (240 mg, 94.4%) consisting of the desired product and its isomer in a ratio of 6:1.
- To a solution of compound 41 (214 mg, 1 mmol) in t-BuOH (9 mL) and H2O (1 mL) at 0° C. is added KMnO4 (237 mg, 1.5 mmol) in portions and the mixture stirred at the same temperature for 2 h. An additional amount (79 mg, 0.5 mmol) of KMnO4 is charged and the mixture is stirred for another 30 minutes. After work up as above, 128 mg (50%) of a mixture of isomers in a ratio of 8:1 is obtained as a white solid in which the major component is the desired product.
- To a solution of compound 41 (214 mg, 1 mmol) in H2O (9 mL) and t-BuOH (1 mL) at 0° C. is added KMnO4 (237 mg, 1.5 mmol) in portions and stirred at the same temperature for 30 minutes. During this time the mixture turns to dark brown. Saturated solution of sodium bisulfite (10 mL) is added to the mixture, which is filtered, and the filtrate is extracted with ethyl acetate (3×25 ml), dried (Na2SO4), and concentrated to give a 4:1 mixture of diol isomers as a white solid (128 mg, 50%), in which the titled compound is the major component.
- A solution of KMnO4 (158 mg, 1.0 mmol) in H2O (10 mL) is added to compound 41 (214 mg, 1 mmol), and the mixture is stirred at 0° C. for 1 hour. The reaction mixture is quenched with saturated solution of sodium bisulfite (10 mL), and the mixture is worked up as above. A white solid (80 mg, 32%) that is obtained is a 4:1 mixture of diol isomers in which the titled compound is the predominant component.
- To a solution of compound 41 (214 mg, 1 mmol) in acetone (10 mL) is added 37.5 mg, 0.1 mmol) and cooled the reaction mixture to 0° C. To this cold solution is added KMnO4 (237 mg, 1.5 mmol) in portions, and the reaction mixture is stirred for 2 h at the same temperature. During this time the reaction mixture turns to dark brown. The reaction mixture is quenched with saturated solution of sodium bisulfite (10 ml) where the solution becomes colorless. The reaction mixture is extracted with ethyl acetate (3×25 ml), dried and evaporated the mixture to give a white solid (245 mg, 96.4%) in the ratio of 10:1.
- To a solution of compound 41 (214 mg, 1 mmol) in a mixture of acetone (9 mL) and pyridine (1 mL) at 0° C. is added KMnO4 (158 mg, 1.0 mmol) and stirred at same temperature for 1 hr. After work up of the reaction mixture as above, 164 mg (67%) of white solid which is practically pure product. Vigorous 1H NMR analyses reveal the crude white solid contains about 6% of the diastereomer of the titled compound.
- In a 50 mL round-bottomed flask equipped with magnetic stirring bar, a mixture of NaIO4(321 mg, 1.5 mmol) and CeCl3.7H2O (37 mg, 0.1 mmol) in 0.45 mL of water is stirred and gently heated until a bright yellow suspension is formed. After cooling to 0° C., EtOAc (1.25 mL) and acetonitrile (1.5 mL) are added and the suspension is stirred for 2 minutes. A 0.1 M aqueous solution of RuCl3 (25 μL) is added and the mixture is stirred for 2 minutes. A solution of the compound 41, (214 mg, 1 mmol) in EtOAc (0.25 mL) is added in one portion and the resulting slurry is stirred at 0° C. for 1 hour. Solid Na2SO4 (0.5 g) is added followed by EtOAc (3 mL). The solid is filtered off, and the filter cake is washed several times with EtOAc. Then the filtrate is washed with saturated Na2SO3 solution and the organic layer is dried (Na2SO4) and concentrated to dryness. The residue is purified by silica gel column chromatography with 20% EtOAc in hexanes to provide a syrup (150 mg, 60%). 1H NMR indicates that the ratio of the desired product to its isomer is approximately 1.6:1.
- To a solution of 3,5-dibenzoyl-2-fluoro-2-deoxy-2-methyl-D-ribono-lactone (49, 23 g, 61.77 mmol, scheme 6) in anhydrous THF (400 ml) was added LiAl (t-OBu)3H (75 mL 1M in THF, 75.0 mmol) over a period of 15 min at −20 to −10° C. and the resulting solution was stirred at the same temperature until all the starting material was consumed. After 5 hours, −10-20% starting material was left, therefore additional 10 mL of LiAl(t-OBu3H (10 mmol) was added at the same temperature and stirred for an hour when TLC indicated all starting material was consumed. To this reaction mixture were added DMAP (7.5 g) and Ac2O (58.2 g, 616 mmol) and the solution was stirred at −10° C. for ˜2-3 h. Upon completion of reaction (as indicated by TLC) the reaction mixture was diluted with ethyl acetate (400 ml) and 200 ml of water. The organic layer was separated and the aqueous layer was washed with ethyl acetate (2×100 ml). The combined organic layer was washed with water (3×150 ml), brine and dried over anhy. Na2SO4. The solvent was removed under reduced pressure and coevaporated with toluene (2×100 mL) to give crude acetate as a clear brown oil. This oil was passed through a plug of silica gel (50 g) and washed with 20% ethyl acetate/hexanes until all the acetate was recovered. The solvent was evaporated under reduced pressure to give the desired acetate (54, 32 g) as a colorless oil.
- To a suspension of N4-benzoylcytosine (20.39 g, 94.74 mmol) in 400 ml of HMDS was added (NH4)2SO4 (250 mg) and heated under reflux for 4 h. Excess HMDS was removed under reduced pressure. The oily residue was dissolved in chlorobenzene (1 L). To this solution were added a solution of the acetate (25 g) in chlorobenzene (250 mL) and SnCl4 (190.4 mmol, 49 g) and the mixture was stirred at room temperature for 2 h followed by heating at ˜65° C. for 16 h. The reaction mixture was cooled to 0° C. to which NaHCO3 (96 g, 1.14 mol) and ethyl acetate (500 ml) were added followed by careful addition of water (20 ml). This mixture was allowed to stir at room temperature for 30 min. The mixture was filtered under vacuum, the residue washed with ethyl acetate. The organic layer was washed with water, brine (2×250 mL) and dried over anhydrous Na2SO4. Solvent was removed under reduced pressure to give a pale yellowish-brown solid. This was dissolved in MeOH (250 mL) heated under reflux for 30 minutes, cooled to room temperature and filtered, to give the desired product (55, 8.0 g) as a off-white solid.
- A suspension of 55 from Example 21 (16.7 g, 30.8 mmol, scheme 6) was treated with methanolic ammonia (750 mL, 7M in MeOH) and stirred at room temperature for 12 h and concentrated to dryness under reduced pressure to give pale yellow solid. THF (400 mL) was added to the solid and heated under reflux for 30 minutes and cooled to room temperature. The solid formed was collected by filtration and washed with THF to give 14 (6.7 g, 88%) as an off-white powder.
Claims (12)
1. A compound of formula
wherein
R′ and R″ are independently H, lower alkyl (C1-C6), aryl (C6-C20), optionally substituted benzyl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, MEM, acetyl, benzoyl, or optionally substituted acyl; or R′ and R″ form a cyclopentyl or cyclohexanyl group;
R1 and R2 are independently H, lower alkyl (C1-C6), aryl (C6-C20), hydroxymethyl, methoxymethyl, halomethyl, optionally substituted ethenyl, halovinyl, optionally substituted ethynyl, or optionally substituted allyl; and
R3 is H, aryl, arylalkyl, or lower alkyl (C1-C6).
2. The compound of claim 1 ,
wherein
R′ and R″ are independently H or lower alkyl (C1-C6);
R1 and R2 are independently H, or lower alkyl (C1-C6); and
R3 is H or lower alkyl (C1-C6).
3. A compound of formula
wherein
each R1 is independently lower alkyl (C1-C6), optionally substituted phenyl, or optionally substituted benzyl; or R1 forms a cyclopentyl or cyclohexanyl group;
R2 and R3 are independently hydrogen, lower alkyl (C1-C6), hydroxymethyl, methoxymethyl, halomethyl, optionally substituted ethenyl, halovinyl, optionally substituted ethynyl, or optionally substituted allyl; and
R4 is independently arylalkyl, or lower alkyl (C1-C10).
4. The compound of claim 3 ,
wherein
each R1 is independently lower alkyl (C1-C6);
R2 and R3 are independently hydrogen, or lower alkyl (C1-C6); and
R4 is independently lower alkyl (C1-C10).
6. A compound of formula
wherein
R2 and R3 are independently H, alkyl (C1-C10), hydroxymethyl, methoxymethyl, halomethyl, optionally substituted ethenyl, halovinyl, optionally substituted ethynyl, or optionally substituted allyl;
R5 and R6 are methoxymethyl, methoxyethyl, benzyloxymethyl, ethoxymethyl, trityl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, acetyl, pivaloyl, benzoyl, toluoyl, 4-phenyl benzoyl, 2-nitrobenzoyl, 3-nitrobenzoyl, 4-nitrobenzoyl, 2-chlorobenzoyl, 3-chlorobenzoyl, 4-chlorobenzoyl, or substituted benzoyl;
Nu is F, Cl, Br, N3, CN, NO3, SCN, OR or NR2 wherein R is acyl or lower alkyl (C1-C10); and
L is a leaving group.
7. The compound of claim 6 ,
wherein
R2 and R3 are independently H, alkyl (C1-C10), or halomethyl;
R5 and R6 are benzoyl;
Nu is F; and
L is OAc.
8. The compound of claim 7 , wherein R2 is H and R3 is methyl.
10. A compound of formula IIIa, IIIb or IIIc
wherein
each R1 is independently lower alkyl (C1-C6), optionally substituted phenyl, or optionally substituted benzyl;
R2 and R3 are independently hydrogen, lower alkyl (C1-C6), hydroxymethyl, methoxymethyl, halomethyl, optionally substituted ethenyl, optionally substituted ethynyl, or optionally substituted allyl; and
R4 is independently hydrogen, aryl, arylalkyl, or lower alkyl (C1-C10).
11. The compound of claim 10 ,
wherein
each R1 is lower alkyl (C1-C6);
R2 and R3 are independently hydrogen, or lower alkyl (C1-C6); and
R4 is lower alkyl (C1-C10).
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/917,173 US20130338349A1 (en) | 2004-09-14 | 2013-06-13 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US14/808,147 US20160024061A1 (en) | 2004-09-14 | 2015-07-24 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US15/425,198 US10577359B2 (en) | 2004-09-14 | 2017-02-06 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60978304P | 2004-09-14 | 2004-09-14 | |
US61003504P | 2004-09-15 | 2004-09-15 | |
US66623005P | 2005-03-29 | 2005-03-29 | |
US11/225,425 US8492539B2 (en) | 2004-09-14 | 2005-09-13 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US13/917,173 US20130338349A1 (en) | 2004-09-14 | 2013-06-13 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/225,425 Continuation US8492539B2 (en) | 2004-09-14 | 2005-09-13 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/808,147 Division US20160024061A1 (en) | 2004-09-14 | 2015-07-24 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130338349A1 true US20130338349A1 (en) | 2013-12-19 |
Family
ID=36060603
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/225,425 Active 2029-12-08 US8492539B2 (en) | 2004-09-14 | 2005-09-13 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US13/917,173 Abandoned US20130338349A1 (en) | 2004-09-14 | 2013-06-13 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US14/808,147 Abandoned US20160024061A1 (en) | 2004-09-14 | 2015-07-24 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US15/425,198 Active 2025-12-18 US10577359B2 (en) | 2004-09-14 | 2017-02-06 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/225,425 Active 2029-12-08 US8492539B2 (en) | 2004-09-14 | 2005-09-13 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/808,147 Abandoned US20160024061A1 (en) | 2004-09-14 | 2015-07-24 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US15/425,198 Active 2025-12-18 US10577359B2 (en) | 2004-09-14 | 2017-02-06 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Country Status (18)
Country | Link |
---|---|
US (4) | US8492539B2 (en) |
EP (2) | EP3109244B1 (en) |
JP (1) | JP5001842B2 (en) |
KR (1) | KR101177590B1 (en) |
AU (1) | AU2005285045B2 (en) |
BR (1) | BRPI0515279A (en) |
CA (1) | CA2580457C (en) |
ES (2) | ES2725457T3 (en) |
HK (1) | HK1130670A1 (en) |
IL (1) | IL181932A (en) |
MX (1) | MX2007003085A (en) |
NZ (1) | NZ554442A (en) |
PL (1) | PL3109244T3 (en) |
PT (1) | PT3109244T (en) |
RU (1) | RU2433124C2 (en) |
SG (2) | SG158136A1 (en) |
SI (1) | SI3109244T1 (en) |
WO (1) | WO2006031725A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9393256B2 (en) | 2011-09-16 | 2016-07-19 | Gilead Pharmasset Llc | Methods for treating HCV |
US10039779B2 (en) | 2013-01-31 | 2018-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US10577359B2 (en) | 2004-09-14 | 2020-03-03 | Gilead Pharmasset Llc | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2604620T (en) * | 2003-05-30 | 2016-09-12 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
CN101023094B (en) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
WO2007075876A2 (en) * | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
DK2084174T3 (en) * | 2006-10-10 | 2013-11-04 | Gilead Pharmasset Llc | Preparation of ribofuranosylpyrimidine nucleotides |
MX2009006156A (en) * | 2006-12-18 | 2009-06-19 | Hoffmann La Roche | Process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-r ibono-gamma-lactone. |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP2268642B1 (en) | 2008-04-23 | 2015-02-25 | Gilead Sciences, Inc. | 1' -substituted carba-nucleoside analogs for antiviral treatment |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
PA8855701A1 (en) | 2008-12-23 | 2010-07-27 | NUCLEOSID ANALOGS | |
JP5713919B2 (en) | 2008-12-23 | 2015-05-07 | ギリアド ファーマセット エルエルシー | Nucleoside phosphoramidate |
DK2396340T3 (en) | 2009-02-10 | 2014-03-10 | Gilead Sciences Inc | Carbanucleosidanaloge to antiviral therapy |
TWI598358B (en) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
PT2480559E (en) | 2009-09-21 | 2013-10-02 | Gilead Sciences Inc | Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs |
WO2011035231A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
JP5872539B2 (en) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | Purine nucleoside phosphoramidate |
PL3290428T3 (en) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
EP2752422B1 (en) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
JP5716500B2 (en) | 2010-06-03 | 2015-05-13 | セントラル硝子株式会社 | Method for producing (2R) -2-fluoro-2-C-methyl-D-ribono-γ-lactone precursors |
KR20200052384A (en) | 2010-07-19 | 2020-05-14 | 길리애드 사이언시즈, 인코포레이티드 | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
ME01924B (en) | 2010-07-22 | 2015-05-20 | Gilead Sciences Inc | Methods and compounds for treating Paramyxoviridae virus infections |
NZ608070A (en) | 2010-09-20 | 2015-11-27 | Gilead Sciences Inc | 2’-fluoro substituted carba-nucleoside analogs for antiviral treatment |
SG188497A1 (en) | 2010-09-22 | 2013-05-31 | Alios Biopharma Inc | Substituted nucleotide analogs |
TW201242974A (en) | 2010-11-30 | 2012-11-01 | Gilead Pharmasset Llc | Compounds |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | Substituted phosphorothioate nucleotide analogs |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
AR091166A1 (en) * | 2012-05-29 | 2015-01-14 | Hoffmann La Roche | PROCESS FOR OBTAINING NUCLEOSID COMPOUNDS 2-DESOXI-2-FLUOR-2-METHYL-D-RIBOFURANOSIL |
CN103724301A (en) * | 2012-10-10 | 2014-04-16 | 上海特化医药科技有限公司 | (2R)-2-desoxy-2,2-disubstituted-1,4-ribonolactones, preparation method and purpose thereof |
US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2909210A4 (en) | 2012-10-17 | 2016-04-06 | Merck Sharp & Dohme | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
JP6394588B2 (en) * | 2013-02-28 | 2018-09-26 | セントラル硝子株式会社 | Process for producing (2R) -2-fluoro-2-C-methyl-D-ribono-γ-lactone |
SI3038601T1 (en) | 2013-08-27 | 2020-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2016035006A1 (en) * | 2014-09-01 | 2016-03-10 | Dr. Reddy’S Laboratories Limited | Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir |
WO2016042576A1 (en) | 2014-09-16 | 2016-03-24 | Cadila Healthcare Limited | Co-crystal of sofosbuvir and amino acid and process for preparation thereof |
CN104327138B (en) * | 2014-10-21 | 2017-05-10 | 齐鲁制药有限公司 | Preparation method of PSI-7977 intermediate compound |
TWI698444B (en) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | Methods for the preparation of ribosides |
CN104610404B (en) * | 2015-01-16 | 2016-04-06 | 南通常佑药业科技有限公司 | A kind of preparation method of ribofuranose phosphate derivative |
UA124966C2 (en) | 2015-03-06 | 2021-12-22 | Атеа Фармасеутікалс, Інк. | <font face="Symbol">b</font>-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N<sup>6</sup>-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
CN106146588A (en) * | 2015-03-26 | 2016-11-23 | 常州制药厂有限公司 | A kind of preparation method of Suo Feibuwei |
EP3310796A1 (en) | 2015-06-22 | 2018-04-25 | Sandoz AG | Synthesis of phosphoramidates |
EP3349758B1 (en) | 2015-09-16 | 2022-04-06 | Gilead Sciences, Inc. | Methods for treating arenaviridae virus infections |
US10344009B2 (en) | 2015-11-03 | 2019-07-09 | Mylan Laboratories Limited | Process for the preparation of sofosbuvir |
CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
US10239910B2 (en) * | 2016-07-20 | 2019-03-26 | Optimus Drugs (P) Limited | Process for the preparation of sofosbuvir |
WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
SG11201906163TA (en) | 2017-02-01 | 2019-08-27 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
KR102460968B1 (en) | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | Methods of treating feline coronavirus infections |
CA3059777C (en) | 2017-05-01 | 2023-02-21 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
EP3651734A1 (en) | 2017-07-11 | 2020-05-20 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
KR20200140865A (en) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | Treatment of HCV-infected patients with cirrhosis |
CN110526950B (en) * | 2019-09-23 | 2023-08-04 | 济南山目生物医药科技有限公司 | Preparation method of alpha-five-O-acetyl mannose |
JP2023512656A (en) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ, インコーポレイテッド | Methods for treating SARS CoV-2 infection |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
EP4132651A1 (en) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
TW202203941A (en) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | Remdesivir treatment methods |
US11939347B2 (en) | 2020-06-24 | 2024-03-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and uses thereof |
MX2023002195A (en) | 2020-08-27 | 2023-03-03 | Gilead Sciences Inc | Compounds and methods for treatment of viral infections. |
CN112058096A (en) * | 2020-09-24 | 2020-12-11 | 朱荣艳 | Nanofiltration membrane and preparation method thereof |
US20230295172A1 (en) | 2022-03-02 | 2023-09-21 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959457A (en) * | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
US8481713B2 (en) * | 2004-07-21 | 2013-07-09 | Gilead Pharmasset Llc | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives |
Family Cites Families (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
NL8403224A (en) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS. |
US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
IL85778A0 (en) | 1987-03-20 | 1988-09-30 | Bristol Myers Co | Production of 2',3'-dideoxynucleosides and certain such novel compounds |
GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
EP0380558A4 (en) | 1987-09-22 | 1991-07-31 | The Regents Of The University Of California | Liposomal nucleoside analogues for treating aids |
SE8802687D0 (en) | 1988-07-20 | 1988-07-20 | Astra Ab | NUCLEOSIDE DERIVATIVES |
US5616702A (en) | 1988-11-15 | 1997-04-01 | Merrell Pharmaceuticals Inc. | 2-'-ethenylidene cytidine, uridine and guanosine derivatives |
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
DE3924424A1 (en) | 1989-07-24 | 1991-01-31 | Boehringer Mannheim Gmbh | NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINAL PRODUCT AND THEIR USE IN THE SEQUENCING OF NUCLEIC ACID |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
AU660925B2 (en) * | 1990-04-06 | 1995-07-13 | Genelabs Technologies, Inc. | Hepatitis C virus epitopes |
WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
AU7623991A (en) | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
JP3347723B2 (en) | 1990-06-13 | 2002-11-20 | グラツィエル,アーノルド | Phosphorus-containing prodrug |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
EP0594677A4 (en) | 1991-07-12 | 1997-09-17 | Vical Inc | Antiviral liponucleosides: treatment of hepatitis b |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
TW224053B (en) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5405598A (en) | 1992-02-24 | 1995-04-11 | Schinazi; Raymond F. | Sensitizing agents for use in boron neutron capture therapy |
US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5256798A (en) * | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
CA2098887C (en) | 1992-06-22 | 2003-10-28 | Ta-Sen Chou | Process for preparing alpha-anomer enriched 1-halo-2-deoxy-2,2-difluoro-d-ribofuranosyl derivatives |
US5426183A (en) * | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
HU214980B (en) * | 1992-09-01 | 1998-08-28 | Eli Lilly And Co. | A process for anomerizing nucleosides |
GB9226729D0 (en) | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
WO1994019012A2 (en) * | 1993-02-24 | 1994-09-01 | Wang Jui H | Compositions and methods of application of reactive antiviral polymers |
WO1994026273A1 (en) | 1993-05-12 | 1994-11-24 | Hostetler Karl Y | Acyclovir derivatives for topical use |
TW374087B (en) | 1993-05-25 | 1999-11-11 | Univ Yale | L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents |
CA2167537A1 (en) | 1993-07-19 | 1995-02-02 | Tsuneo Ozeki | Hepatitis c virus proliferation inhibitor |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US7375198B2 (en) * | 1993-10-26 | 2008-05-20 | Affymetrix, Inc. | Modified nucleic acid probes |
KR960705579A (en) | 1993-11-10 | 1996-11-08 | 에릭에스. 딕커 | Improved interferon polymer conjugates |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
WO1995024185A1 (en) | 1994-03-11 | 1995-09-14 | Isis Pharmaceuticals, Inc. | Novel pyrimidine nucleosides |
DE4415539C2 (en) * | 1994-05-03 | 1996-08-01 | Osama Dr Dr Med Omer | Plants with virustatic and antiviral effects |
JPH10501809A (en) * | 1994-06-22 | 1998-02-17 | ネクスター ファーマスーティカルズ,インコーポレイテッド | Novel method for producing known and novel 2'-nucleosides by intramolecular nucleophilic substitution |
DE4432623A1 (en) * | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Process for bleaching aqueous surfactant solutions |
US5559101A (en) | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US6391859B1 (en) * | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
DE19514523A1 (en) | 1995-04-12 | 1996-10-17 | Schering Ag | New cytosine and cytidine derivatives |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
GB9602028D0 (en) * | 1996-02-01 | 1996-04-03 | Amersham Int Plc | Nucleoside analogues |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
AU2064297A (en) * | 1996-02-29 | 1997-09-16 | Immusol, Inc | Hepatitis c virus ribozymes |
US5633388A (en) * | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
PL329681A1 (en) | 1996-05-01 | 1999-04-12 | Lilly Co Eli | Halogen-substituted inhibitor of proteinous kinase c |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
US5891874A (en) * | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
US5837257A (en) | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
US5922757A (en) * | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
UA63915C2 (en) | 1996-10-16 | 2004-02-16 | Ай-Сі-Ен Фармасьютикалз, Інк. | Monocyclic l-nucleosides, analogues and use thereof |
US6455690B1 (en) | 1996-10-16 | 2002-09-24 | Robert Tam | L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine |
EP0961775B1 (en) * | 1996-10-16 | 2004-07-14 | ICN Pharmaceuticals, Inc. | Purine l-nucleosides, analogs and uses thereof |
US6509320B1 (en) | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
HU227742B1 (en) | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
IL119833A (en) * | 1996-12-15 | 2001-01-11 | Lavie David | Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
US20020127371A1 (en) * | 2001-03-06 | 2002-09-12 | Weder Donald E. | Decorative elements provided with a circular or crimped configuration at point of sale or point of use |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
EP1009732B1 (en) * | 1997-06-30 | 2003-05-21 | MERZ + CO. GmbH & Co. | 1-amino-alkylcyclohexane nmda receptor antagonists |
TW434252B (en) | 1997-07-23 | 2001-05-16 | Univ Georgia Res Found | Process for the preparation of 2'-fluoro-5-methyl-β-L-arabino-furanosyluridine |
JP4452401B2 (en) | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム (カナダ) リミテッド | Hepatitis C virus inhibitory peptide analog |
EP1317929A3 (en) | 1997-09-21 | 2003-07-02 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection |
US6703374B1 (en) * | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
EP1058686B1 (en) | 1998-02-25 | 2006-11-02 | Emory University | 2'-fluoronucleosides |
US6787305B1 (en) | 1998-03-13 | 2004-09-07 | Invitrogen Corporation | Compositions and methods for enhanced synthesis of nucleic acid molecules |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
CN1230198C (en) | 1998-05-15 | 2005-12-07 | 先灵公司 | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having G chronic hepatitis C infection |
HU228218B1 (en) | 1998-06-08 | 2013-02-28 | Hoffmann La Roche | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
CN100387237C (en) | 1998-08-10 | 2008-05-14 | 艾丹尼克斯(开曼)有限公司 | Beta-L-2'deoxy-nucleosides for the treatment of hepatitis B |
FR2784892B1 (en) | 1998-10-23 | 2001-04-06 | Smith & Nephew Kinetec Sa | FOLDABLE PASSIVE MOBILIZATION BRACKET FOR LOWER MEMBER |
JP2003507322A (en) | 1998-12-18 | 2003-02-25 | シェリング・コーポレーション | Ribavirin-PEGylated interferon-α-induced HCV combination therapy |
EP1225899A2 (en) | 1999-11-04 | 2002-07-31 | Virochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
TR200601784T2 (en) * | 1999-11-12 | 2007-01-22 | Pharmasset Ltd. | Synthesis of 2'-deoxy-L-nucleosides |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
CZ20022825A3 (en) | 2000-02-18 | 2003-05-14 | Shire Biochem Inc. | Nucleoside analogs intended for use when treating or prophylaxis infections induced by flavivirus |
ES2319732T3 (en) | 2000-04-13 | 2009-05-12 | Pharmasset, Inc. | DERIVATIVES OF NUCLEOSIDE 3'- OR 2'-HYDROXIMETHYL REPLACED FOR THE TREATMENT OF VIRAL INFECTIONS. |
WO2001081359A1 (en) | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
WO2001092282A2 (en) * | 2000-05-26 | 2001-12-06 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
ES2227203T3 (en) | 2000-05-26 | 2005-04-01 | Idenix (Cayman) Limited | METHODS TO TREAT INFECTION WITH THE DELTA HEPATITIS VIRUS WITH BETA-1-2'-DEOXINUCLEOSIDS. |
FR2810322B1 (en) * | 2000-06-14 | 2006-11-10 | Pasteur Institut | COMBINATORY PRODUCTION OF NUCLEOTIDE AND NUCLEOTIDE ANALOGUES (XiTP) |
MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
UA72612C2 (en) * | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
WO2002008251A2 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
AR029851A1 (en) | 2000-07-21 | 2003-07-16 | Dendreon Corp | NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
HUP0303358A3 (en) | 2000-07-21 | 2005-10-28 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them |
AR034127A1 (en) | 2000-07-21 | 2004-02-04 | Schering Corp | IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
AR039558A1 (en) * | 2000-08-21 | 2005-02-23 | Inspire Pharmaceuticals Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION |
US7018985B1 (en) * | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US6897201B2 (en) * | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
JP2004511513A (en) | 2000-10-18 | 2004-04-15 | シェリング・コーポレーション | Ribavirin-PEGylated interferon alpha HCV combination therapy |
EP2251015B1 (en) | 2000-10-18 | 2013-02-20 | Gilead Pharmasset LLC | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
US6555677B2 (en) * | 2000-10-31 | 2003-04-29 | Merck & Co., Inc. | Phase transfer catalyzed glycosidation of an indolocarbazole |
AU2002248147B2 (en) | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
DE20019797U1 (en) | 2000-11-21 | 2001-04-05 | Mala Verschlussysteme Gmbh | Sealing cap |
KR20030091946A (en) | 2000-12-12 | 2003-12-03 | 쉐링 코포레이션 | Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus |
AU2002230764A1 (en) | 2000-12-13 | 2002-06-24 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
US6750396B2 (en) | 2000-12-15 | 2004-06-15 | Di/Dt, Inc. | I-channel surface-mount connector |
CA2429352A1 (en) | 2000-12-15 | 2002-06-20 | Lieven Stuyver | Antiviral agents for treatment of flaviviridae infections |
US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
SI1355916T1 (en) | 2001-01-22 | 2007-04-30 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
GB0112617D0 (en) | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
US6962991B2 (en) | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
WO2003022861A1 (en) | 2001-09-13 | 2003-03-20 | Bristol-Myers Squibb Company | Process for the preparation of rebeccamycin and analogs thereof |
WO2003024461A1 (en) | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
WO2003026589A2 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
GB0129945D0 (en) | 2001-12-13 | 2002-02-06 | Mrc Technology Ltd | Chemical compounds |
BR0214944A (en) | 2001-12-14 | 2005-06-07 | Pharmasset Ltd | N4-Acylcytosine Nucleosides for the Treatment of Viral Infections |
AU2002353165A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
JP2005514401A (en) * | 2001-12-21 | 2005-05-19 | マイクロロジックス バイオテック,インコーポレイテッド | Antiviral 7-deaza L-nucleoside |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
US7323453B2 (en) * | 2002-02-13 | 2008-01-29 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
AU2003213628A1 (en) * | 2002-02-28 | 2003-09-16 | Biota, Inc. | Nucleoside 5'-monophosphate mimics and their prodrugs |
US7285658B2 (en) * | 2002-02-28 | 2007-10-23 | Biota, Inc. | Nucleotide mimics and their prodrugs |
AU2003241621A1 (en) * | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
AU2003248708A1 (en) | 2002-06-17 | 2003-12-31 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
WO2003105770A2 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
WO2004000858A2 (en) | 2002-06-21 | 2003-12-31 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
WO2004003138A2 (en) | 2002-06-27 | 2004-01-08 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
KR20050035194A (en) | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CA2490200C (en) | 2002-06-28 | 2012-01-03 | Idenix (Cayman) Limited | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
ES2469569T3 (en) | 2002-06-28 | 2014-06-18 | Idenix Pharmaceuticals, Inc. | 2 'and 3' modified nucleoside prodrugs for the treatment of Flaviviridae infections |
US20060264389A1 (en) * | 2002-07-16 | 2006-11-23 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US7323449B2 (en) * | 2002-07-24 | 2008-01-29 | Merck & Co., Inc. | Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
EP1572709A3 (en) | 2002-07-24 | 2005-11-23 | PTC Therapeutics, Inc. | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases |
AU2003254657A1 (en) * | 2002-07-25 | 2004-02-16 | Micrologix Biotech Inc. | Anti-viral 7-deaza d-nucleosides and uses thereof |
PT1572095E (en) * | 2002-09-13 | 2015-10-13 | Novartis Ag | Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains |
KR20050088079A (en) * | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-branched nucleosides and flaviviridae mutation |
WO2004052905A2 (en) * | 2002-12-10 | 2004-06-24 | F. Hoffmann-La Roche Ag | Antiviral nucleoside derivatives |
CA2509687C (en) | 2002-12-12 | 2012-08-14 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
WO2004080466A1 (en) | 2003-03-07 | 2004-09-23 | Ribapharm Inc. | Cytidine analogs and methods of use |
CN101415719A (en) | 2003-03-20 | 2009-04-22 | 微生物化学及药品有限公司 | Methods of manufacture of 2 -deoxy-beta-L-nucleosides |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
CA2522845A1 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
KR20060061930A (en) | 2003-04-25 | 2006-06-08 | 길리애드 사이언시즈, 인코포레이티드 | Anti-cancer phosphonate analogues |
US7452901B2 (en) * | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
PT1628685E (en) | 2003-04-25 | 2011-03-16 | Gilead Sciences Inc | Antiviral phosphonate analogs |
US20050261237A1 (en) | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
CN1812995A (en) | 2003-04-28 | 2006-08-02 | 艾登尼科斯(开曼)有限公司 | Industrially scalable nucleoside synthesis |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
WO2005020884A2 (en) | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
LT2604620T (en) * | 2003-05-30 | 2016-09-12 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
WO2005007810A2 (en) | 2003-06-16 | 2005-01-27 | Grinstaff Mark W | Functional synthetic molecules and macromolecules for gene delivery |
DE10331239A1 (en) | 2003-07-10 | 2005-02-03 | Robert Bosch Gmbh | Monitoring electronics for an electric motor and method for monitoring an electric motor |
GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
KR20060084845A (en) | 2003-07-25 | 2006-07-25 | 이데닉스 (케이만) 리미티드 | Purin nucleoside analogues for treating flaviviridae including hepatitis c |
JP2007504152A (en) | 2003-08-27 | 2007-03-01 | ビオタ, インコーポレイテッド | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
US7026339B2 (en) | 2003-11-07 | 2006-04-11 | Fan Yang | Inhibitors of HCV NS5B polymerase |
AU2005208887B2 (en) | 2004-01-28 | 2010-02-25 | Merck Sharp & Dohme Corp. | Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity |
BRPI0512360A (en) | 2004-06-23 | 2008-03-11 | Idenix Cayman Ltd | 5-aza-7-deazapurine derivatives for the treatment of flaviviridae |
MX2007000803A (en) * | 2004-07-21 | 2007-04-02 | Pharmasset Inc | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives. |
WO2006029081A2 (en) | 2004-09-02 | 2006-03-16 | Neopharm, Inc. | Nucleoside-lipid conjugates, their method of preparation and uses thereof |
CA2580457C (en) | 2004-09-14 | 2014-11-04 | Pharmasset, Inc. | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
BRPI0515896A (en) | 2004-09-24 | 2008-08-12 | Idenix Cayman Ltd E Ct Nat De | a compound or a pharmaceutically acceptable salt or ester thereof, a method for treating or prophylaxis a host infected with a flavivirus, pestivirus or hepacivirus infection, and a pharmaceutical composition for treating a host infected with a flavivirus, pestivirus or hepacivirus |
WO2006065335A2 (en) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
GB0427123D0 (en) | 2004-12-11 | 2005-01-12 | Apv Systems Ltd | Food item coating apparatus and method |
DK2084174T3 (en) * | 2006-10-10 | 2013-11-04 | Gilead Pharmasset Llc | Preparation of ribofuranosylpyrimidine nucleotides |
-
2005
- 2005-09-13 CA CA2580457A patent/CA2580457C/en active Active
- 2005-09-13 SI SI200532250T patent/SI3109244T1/en unknown
- 2005-09-13 MX MX2007003085A patent/MX2007003085A/en active IP Right Grant
- 2005-09-13 SG SG200908300-7A patent/SG158136A1/en unknown
- 2005-09-13 KR KR1020077008620A patent/KR101177590B1/en active IP Right Grant
- 2005-09-13 JP JP2007532391A patent/JP5001842B2/en active Active
- 2005-09-13 EP EP16164767.2A patent/EP3109244B1/en active Active
- 2005-09-13 PT PT16164767T patent/PT3109244T/en unknown
- 2005-09-13 ES ES16164767T patent/ES2725457T3/en active Active
- 2005-09-13 AU AU2005285045A patent/AU2005285045B2/en active Active
- 2005-09-13 NZ NZ554442A patent/NZ554442A/en not_active IP Right Cessation
- 2005-09-13 ES ES05808357T patent/ES2769377T3/en active Active
- 2005-09-13 SG SG2013046164A patent/SG192409A1/en unknown
- 2005-09-13 PL PL16164767T patent/PL3109244T3/en unknown
- 2005-09-13 EP EP05808357.7A patent/EP1809301B1/en active Active
- 2005-09-13 WO PCT/US2005/032406 patent/WO2006031725A2/en active Application Filing
- 2005-09-13 US US11/225,425 patent/US8492539B2/en active Active
- 2005-09-13 RU RU2007113918/04A patent/RU2433124C2/en not_active IP Right Cessation
- 2005-09-13 BR BRPI0515279-8A patent/BRPI0515279A/en not_active Application Discontinuation
-
2007
- 2007-03-14 IL IL181932A patent/IL181932A/en not_active IP Right Cessation
-
2009
- 2009-09-24 HK HK09108744.3A patent/HK1130670A1/xx unknown
-
2013
- 2013-06-13 US US13/917,173 patent/US20130338349A1/en not_active Abandoned
-
2015
- 2015-07-24 US US14/808,147 patent/US20160024061A1/en not_active Abandoned
-
2017
- 2017-02-06 US US15/425,198 patent/US10577359B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959457A (en) * | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
US8481713B2 (en) * | 2004-07-21 | 2013-07-09 | Gilead Pharmasset Llc | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives |
Non-Patent Citations (1)
Title |
---|
Lopez Aparicio et al., Carbohydrate Research, vol 129, pp 99-109, 1984. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10577359B2 (en) | 2004-09-14 | 2020-03-03 | Gilead Pharmasset Llc | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US9393256B2 (en) | 2011-09-16 | 2016-07-19 | Gilead Pharmasset Llc | Methods for treating HCV |
US10456414B2 (en) | 2011-09-16 | 2019-10-29 | Gilead Pharmasset Llc | Methods for treating HCV |
US10039779B2 (en) | 2013-01-31 | 2018-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10577359B2 (en) | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives | |
US7601820B2 (en) | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives | |
EP1773856B1 (en) | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives | |
JP2008507547A6 (en) | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PHARMASSET, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHUN, BYOUNG-KWON;WANG, PEIYUAN;DU, JINFA;AND OTHERS;SIGNING DATES FROM 20060126 TO 20060127;REEL/FRAME:030840/0226 Owner name: GILEAD PHARMASSET LLC, CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:PHARMASSET, INC.;REEL/FRAME:030843/0272 Effective date: 20120210 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |